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The socioeconomic impact of non-treatment of brain disorders, particularly when it comes to mental 
health illnesses, is shocking. A recent OECD report entitled “Making Mental Health Count” points out 
that health, social, and employment services should intervene earlier, involve key stakeholders and 
ensure they work together with the community in order to help people with mental health issues not 
only to tackle these but also be able to find work or stay in a job. The case study of schizophrenia 
provides a revealing example of a highly prevalent mental health condition that can still account for a 
large proportion of individuals that are not diagnosed, do not get any evidence-based treatment, or 
are likely to receive diagnosis and treatment with years of delay.  Still, evidence shows that, if they are 
enrolled in appropriate treatment programmes, they can struggle to overcome non-adherence issues. 
This report takes the forefront position to be used as important source of information for academic, as 
well as policy and practitioner stakeholders when looking into the multidimensional impact that non-
treatment of schizophrenia has on the use of health and social care resources, criminal justice 
services, employment, education, violence and premature death, and homelessness. The voices 
emerging from the literature and the international community of experts that supported this work are in 
agreement to recommend urgent collaborative reform initiatives, which involve all parties. For 
example, stigma and negative perceptions about psychiatric care and schizophrenia, poor 
collaboration among the different types of providers, lack of continuity of care or appropriate clinician 
training are listed within the most common barriers to changes for patients/their caregivers, healthcare 
systems and providers, respectively. 
Policy interventions that may respond to the growing urgency of the problem should target: 
engagement with, and empowerment of, people with schizophrenia, their families, and their 
communities; better use of integrated interventions; and ensuring that services are easily accessible 
by patients. Measuring unmet needs allows to have a better understanding of the scale of the 
problem, and what works in tackling it. Crucially, this report is a first step towards addressing a 
worrying lack of evidence of the impact of unmet needs in schizophrenia beyond local settings or 
country specific evaluations, as well as making us all aware of the challenges that need to be 
overcome to support future research. 
What is more, this study is part of the broader investigation by the European Brain Council (EBC) of 
the cost of non-treatment of brain disorders in Europe. By providing an extensive review of the case 
for schizophrenia, it sheds light on the crucial issues to be looked at and provides for a robust 
methodology that can be translated to the other conditions to be considered in EBC’s broader study. 
 
 
Frédéric Destrebecq 
Executive Director, European Brain Council 
PREFACE 
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• Unmet needs in schizophrenia arise from a discrepancy between the use of mental 
health services and the extent of need for those services. 
 
• The impact of non-treatment is extensive and reveals a complex scenario with strong 
interrelationships between the individual, community, and providers of mental 
health services. 
 
• There are still considerable gaps in our current knowledge about the impact of non-
treatment in schizophrenia. The limited quality evidence reports on access to 
hospital facilities and emergency services, number of violent acts and loss of 
productivity at work (the USA as predominant setting). More evidence is needed to 
go beyond the clinical settings and cover the community overall as well as subgroups 
of people in stronger need (homelessness, prisoners and younger individuals). 
 
• The economic data available are very limited, but still show a massive impact of 
unmet needs on healthcare and society overall. The overall number of cases of 
untreated schizophrenia is estimated to be about 8.5 million worldwide (3 million 
cases between Europe and the Americas). The overall economic burden would be 
about 56 billion US$ (20 billion US$ between Europe and the Americas). 
 
• We found a broad agreement about the changes that need to be made to address 
unmet needs in schizophrenia, and they involve all parties: patients, caregivers, 
healthcare providers and healthcare systems. 
 
  
EXECUTIVE SUMMARY 
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Unmet needs in schizophrenia arise from a discrepancy between the use of 
mental health services and the extent of need for those services. 
 
• The impact of non-treatment is extensive and involves strong interrelationships 
between the individual, community, and providers of mental health services. 
 
• Non-treatment may occur at different levels of the patient pathway to include: 
missed (or delays in) diagnosis, lack of (or delays in) treatment, inappropriate 
treatment and non-adherence/non-compliance. 
 
• The negative outcomes derived from unmet needs cover a cascade of interrelated 
factors including: unnecessary physical/mental disability and comorbidities that may 
require access to health and social care resources; experience of criminal justice 
system; reduced productivity in the workplace or employment; disrupted education; 
violence and premature death (suicides and homicides); and homelessness. 
 
• Against this background, the impact of non-treatment in terms of indirect costs 
(community, education and workspace), direct healthcare costs (primary setting, 
hospital and community), direct non-medical costs (social services, special 
accommodation and informal care), social security and criminal justice costs is 
massive. 
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From our evidence, we conclude that it is unacceptable that: 
There are still considerable gaps in our current knowledge about the impact of non-
treatment in schizophrenia. The limited quality evidence reports only on:  
• A few outcomes (access to hospital facilities and emergency services; number of 
violent acts and loss of productivity at work). More evidence should be gathered on 
the economic impact of increased access to the criminal justice system, 
homelessness as well as of the burden of additional physical comorbidities and 
disabilities.  
 
• Adult patients approaching clinical settings. More research is needed to address 
unmet needs across groups of population in needs (including the homeless, 
prisoners, and younger individuals) and settings (to collect also population level 
data).      
 
• Delays in treatment or treatment discontinuation (non-adherence/compliance).  
More quality evidence is needed to cover earlier steps in the patient pathway (e.g. 
missed and delays in diagnosis at population level).   
The limited economic evidence shows a massive impact of unmet needs on healthcare and 
society overall: 
• In Canada the impact of undiagnosed psychosis (including schizophrenia) on the use 
of health resources (Lim et al., 2008) shows that the annual medical cost per capita is 
highest for the diagnosed mentally ill (C$2,515), lowest for the non-mentally ill 
(C$6430, with those in the undiagnosed category in the middle (C$1,442; Canada, 
2003 figures).  
 
• In the USA (Greater Kansas City) the annual cost of lack of treatment for severe 
mental illness (SMI) is about $6609 per case, 2010 figures (HSM Group, 2012). A high 
proportion (88%) of these costs is in the form of indirect costs to employers and 
individuals (about U$5785 per case of untreated SMI). About 10 % of the overall 
costs are estimated to be direct costs, or medical expenses associated with lack of 
sustained treatment (about US$696 per case of untreated SMI).  
 
When adapting the Greater Kansas City model to international estimates of the 
prevalence and treatment gap for schizophrenia, the overall number of cases of 
untreated schizophrenia would be around 8.5 million worldwide, with about 3 
million cases between Europe and the Americas. The overall economic burden would 
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be about 56 billion US$ worldwide (20 billion US$ between Europe and the Americas 
only). 
• In the USA the national re-hospitalization cost attributable to antipsychotic non-
adherence is estimated at approximately US$1,500 million per year (2005 figures). 
Patchy evidence across country settings highlights also the impact of non-adherence / non –
compliance to psychotic treatment on: incarceration rates, unemployment rates and work 
loss, level of education achieved, or withdrawal from education, violence (self-harm or 
aggressive behaviour towards others) and death (suicides, homicides). 
 
Addressing the non-treatment of schizophrenia is an important goal to be 
met, with numerous challenges! The main barriers to be overcome involve us 
all: 
The patients and caregivers 
• Stigma and negative perceptions about psychiatric care and schizophrenia; Suffering 
from psychotic symptoms or cognitive impairment; Lack of knowledge about side 
effects of medications; Lack of skills or management strategies to cope with side 
effects; Lack of illness awareness/not knowing what to do; Limited access to 
treatment; Previous history of non-adherence, substance abuse; Caregiver/patient 
personal beliefs of healthcare providers. 
Healthcare providers 
• Lack of training in the interpersonal skills; Lack of continuity of care with a single 
clinician; Poor quality of communication and collaboration between the providers 
and the patients; Lack of appropriate training or education on schizophrenia; Lack of 
appropriate information on schizophrenia; Shift of the attention to other 
phenomena that have become “medicalised”; Attitude of all staff towards the 
patients; Lack of time for motivational interventions, trust building and 
establishment of a therapeutic relationship; Under-representation of 
psychotherapeutic approaches in treatment of patients with SMI. 
Healthcare system  
• Poor collaboration among the different types of providers; Difficulties in providing 
the appropriate service; The system discourages the proper monitoring of patients 
once the treatment regimen is started; Lack of community services and integration 
between health and social care; Scarce attempt to make a patient feel welcome, 
empowered and valued.  
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Researchers evaluating the impact of unmet needs 
• Limited access to data on homelessness, prisoners, and younger individuals; 
Discrepancies in the information system that supports the management of care or in 
the methods used when assessing patient non-adherence/non-compliance as well as 
their self-reported outcomes (e.g. quality of life); Lack of comprehensive evaluation 
of the patient pathway of care from diagnosis, primary/hospital care to community 
services. 
We found also broad agreement about the changes that need to be made to 
transform the lives of those with unmet needs and of their families. Our 
recommendations include: 
• Stigma and negative perception about schizophrenia are top priorities in all 
countries. Awareness campaigns aimed at the general public can be beneficial in 
increasing awareness of the nature of schizophrenia and its treatment. 
 
• Promoting patient-centred care to ensure continuity of care, develop partnerships 
with caregivers and patients, support patient and stakeholder involvement in 
decision making,  treat the patient as a person and not only “the symptoms”.   
 
• Assisting patients/their caregivers from diagnosis to their access to hospital and 
community care and ensuring that services are easily accessible by users. 
 
• Promoting and implementing community care, with a focus on integrating health 
and social care. 
 
• Supporting communication and collaboration across healthcare providers and co-
ordination of mental health services across settings. 
 
• Providing appropriate training and information to providers and patients. 
 
• Using appropriate mechanisms for measurement of quality care. 
 
• Overcoming discrepancies in electronic information system or in the assessment of 
non-adherence/non-compliance across settings. 
 
• Drawing attention to hard-to-reach groups in need (e.g. prisoners, homeless or 
younger individuals). 
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Schizophrenia is a highly burdensome condition in numerous countries.  It is estimated that 
at least 26 million people worldwide have schizophrenia, and twice as many individuals (e.g. 
as caregivers) are indirectly affected by it (World Health Organisation, 2004). This has a 
substantial impact on everyday functioning, being one of the top ten causes of disability in 
individuals under the age of 25. In most cases, individuals who develop schizophrenia 
manifest behavioural and cognitive changes prior to the formal diagnosis of the condition 
(Cooke, 2014). Clinicians face various challenges in diagnosing this disorder, as well as in 
designing treatment plans that will reduce negative symptoms, maximize adherence and 
reduce side effects. Against this background, the impact of schizophrenia in terms of 
mortality, social disability, social stigma, impact on caregivers, and social costs is massive.  
The protection and treatment of people with mental disorders is recognised by the United 
Nations as a fundamental human right (United Nations, 1991). All affected individuals 
should be helped to live a life free from prejudice, discrimination, and hostility. They have 
the right to: be protected from abuse and from behaviour, attitudes, and assumptions that 
lead to exclusion; and access health care and benefit from the best available treatment 
(Fleischhacker et al., 2014).  
As well as the potential human cost, the burden of schizophrenia and other mental health 
disorders is very high on health care resources and on society as they contribute to 
increased hospitalisation and emergency care, physical comorbidities and premature death, 
school absence, access to criminal justice system for violent act, unemployment, sickness 
absence, and lost productivity at work (OECD, 2014).  
The objectives of part 1 of the report are to define the problem of unmet needs in 
schizophrenia and define the key outcomes of the social and economic impact of untreated 
schizophrenia. A conceptual framework is presented to summarise the aspects involved 
when dealing with unmet needs of people with schizophrenia and their economic and social 
impact. 
 
  
PART 1- DEFINING THE PROBLEM 
AND ITS SOCIAL AND ECONOMIC 
IMPACT 
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The problem: untreated schizophrenia is due to 
a structural imbalance in the mental care 
sector 
 
The core of the problem lies in a ‘structural imbalance’ where 'unmet needs' arise with a 
lack of correspondence between the use of mental health services and the extent of need 
for those services  (Doessel, Williams, & Whiteford, 2010) (see figure 1). 
What ‘unmet needs’ are 
Evidence shows that shortages in mental health services mean that some individuals 
experience missed (or delays in) diagnosis.  Others that have been diagnosed and are in 
contact with mental health services may report lack of treatment; not receive appropriate 
treatment according to evidence; be non-adherence/non-compliance; or experience delays 
or insufficient treatment (Doessel et al., 2010) (OECD, 2014). 
  
Figure 1: ‘Structural imbalance’ between population with schizophrenia 
and population using health and social care resources for schizophrenia; 
adapted from (Doessel et al., 2010) 
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Identifying ‘unmet needs’ 
Several approaches are available to identify ‘unmet needs’, and they include both 
assessment in clinical setting (e.g. to measure delays in access to care, inappropriate 
treatment, or non-adherence to medication) as well as analysis of data collected at 
population/community level (e.g. to measure missed (or delays in) diagnosis), using 
epidemiological and perceived need for care surveys (Doessel et al., 2010) (Mojtabai et al., 
2009). 
There is a particular difficulty when determining the extent of ‘unmet needs’ for mental 
health services. Data sets on utilisation of resources (e.g. hospital administrative data or 
public/private insurance claims) can produce an incomplete picture of health status in the 
community because of several financial and social barriers to accessing health services that 
may prevent people to be diagnosed or result in delays in diagnosis. Complementary 
community data are therefore needed, looking not only at people who accessed but also at 
those who did not access the resources.  
Another matter reported in the literature refers to 'met non-need'; people who use mental 
health services and do not have a diagnosis of schizophrenia. For example they can include: 
the ‘worried well’, where everyday stress and sadness are ‘medicalised’ as mental health 
illnesses; or individuals who want to improve sport and managerial performances may be 
supported by mental health professionals and receive mental health care (Doessel et al., 
2010). 
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The impact: negative outcomes derived from 
unmet needs 
  
• Untreated or under-treated schizophrenia often sets in motion and perpetuates a 
cascade of increasing mental instability and other negative outcomes to include:  
unnecessary physical and mental disability; reduced productivity in the workplace or 
unemployment; divorce and family instability; disrupted education; violence and 
death (homicides, suicides); experience of criminal justice system for violent acts; 
homelessness.  
 
• There is a significant association between schizophrenia and several somatic 
disorders such as nutritional/metabolic disorders, cardiovascular conditions, and 
sexual dysfunctions.  Obesity, diabetes, and smoking are two times more frequently 
seen among patients with schizophrenia and other mental health disorders than in 
the general population (Torres-González et al., 2014). These conditions may 
compromise medication adherence and access to treatment as well as the quality of 
life of patients with schizophrenia (see figure 2).  
 
All these negative outcomes are usually associated with increased costs of all resources 
used to include: indirect costs, direct healthcare costs, direct non-medical costs and other 
costs (OECD, 2012 and 2014).  
Indirect costs (community, education and workspace) - Over 80 percent of these costs are 
related to morbidity, including the reduced or lost education/productivity due to illness 
(States, Project, & Metro, 2003). An even greater problem for employers is presenteeism, or 
lost productivity while at work. Research has shown that employees with untreated mental 
illness are far less productive compared to those who are successfully treated (Goetzel et 
al., 2004). They also include the school dropout and juvenile justice involvement with long 
term impact on adulthood productivity.  Loss of productivity may also include premature 
deaths (mortality costs), homelessness of the individual with mental illness and the support 
costs of individuals providing care for family members with mental illness. These indirect 
cost estimates are conservative because they do not usually capture some measure of the 
pain, suffering, disruption and reduced productivity that are reflected in lost earnings.  
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Figure 2 – Unmet needs in schizophrenia: a conceptual framework 
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Direct health care costs (primary setting, hospital and community) - Direct health care 
costs are costs for treatment and care services that fall on the government purse. These 
include medical resources used for care, treatment, and rehabilitation. Research has shown 
that untreated mental illness can lead to the need for much more resource-intensive care 
than if the patient were getting regular care and treatment (Wu et al., 2005). For example 
the schizophrenia patients may visit the emergency department in crisis mode and require 
hospitalisation until they are stable.  
Direct non-medical costs (institutionalisation and community) - These include social 
services, special accommodation and informal care. Additionally, due to lack of treatment, 
the illness can progress to a point where patients need to be institutionalised (e.g. in nursing 
homes or long-term care facilities). 
Other costs (social security and criminal justice) - Going without treatment can lead to 
more severe, more difficult-to-treat illness or even to permanent disability. Additional costs 
may include public expenditure related to the social security and the criminal justice 
systems. For example poor mental health can bring negative social consequences, such as  
higher expenditures on disability benefits, (OECD, 2012), as well as increased crime when 
patients with schizophrenia and other severe mental illnesses are 10 times more likely to 
become incarcerated compared to the general population (Prince, Akincigil, & Bromet, 
2007).  
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Key messages 
 
• The issue of unmet needs in schizophrenia arises from a discrepancy between the 
use of mental health services and the extent of need for those services. 
 
• The impact of non-treatment is extensive and reveals a complex scenario with strong 
interrelationships between the individual, community, and providers of mental 
health services. 
 
• Unmet needs cover missed (or delays in) diagnosis, lack of (or delays in) treatment, 
inappropriate treatment and non-adherence/non-compliance. 
 
• The key outcomes of the social and economic impact of untreated schizophrenia 
includes: health and social care resources, comorbidities; use of criminal justice 
resources; employment; education; violence and premature death; and 
homelessness. 
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Globally, the total costs – direct and indirect – of mental health (including moderate and 
severe mental illnesses such as schizophrenia) were estimated at USD 2 493 billion in 2010. 
In the EU, the cost was estimated to be equivalent to a loss of 3-4% of total GDP in 2004 
(OECD, 2014).  From a public health perspective, the unmet needs of persons with 
schizophrenia (who have not made contact with health services or if they have done so they 
received treatment with delay, they did not receive appropriate treatment or they were not 
adherent to their medications) are also a major problem. For example the treatment gap 
(percentage difference between number of people needing treatment and number of 
people receiving treatment) for schizophrenia worldwide is 32% (Kohn, Saxena, Levav, & 
Saraceno, 2004).  
The indirect costs of mental health – the economic consequences attributable to disease, 
illness, or injury resulting in lost resources, but which do not involve direct payments related 
to the disease – are particularly high in both treated and non-treated groups. This includes 
the value of lost production due to unemployment, absences from work, presenteeism1 or 
premature mortality (OECD, 2012). Across OECD countries, 88% of workers with 
schizophrenia or other severe mental illnesses stated that they accomplished less than they 
would like as a result of an emotional or physical problem, compared to 69% of those with 
moderate mental illness, and 26% of those with no mental illness. Unemployment is also a 
key issue for those individuals; they are typically six to seven times more likely to be 
unemployed than people with no such illnesses (OECD 2014). 
An international survey aimed at exploring the opinions of the World Psychiatric Association 
(WPA) representatives regarding strategies to increase coverage of services, with a focus on 
areas where mental health specialists are scarce. Schizophrenia was defined as top priority 
for future health services redesign at international level (Patel et al., 2010). A series of policy 
actions, based on research evidence, stakeholder consultation, and examples of best 
practice worldwide, have been recently published to provide guidance to policy makers and 
all relevant stakeholders who influence care quality for schizophrenia, and supports their 
commitment to creating a better future (Fleischhacker et al., 2014).  
According to the OECD reporting on the social and economic costs of neglecting mental 
health care (OECD 2014), a series of initiatives are suggested to respond better to the 
growing urgency of poor mental health. One of those covers measuring the burden of 
                                                     
1
 The loss in productivity that occurs when employees come to work even when unwell and 
consequently function at less than full capacity. 
PART 2- EVIDENCE FROM THE 
INTERNATIONAL LITERATURE  
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mental health to society (including also non-treatment) to better understand the scale of 
the problem and what works in tackling it. However, there is little information on almost all 
aspects of mental health in OECD countries, which means that policy makers cannot fully 
understand the scale of the challenge of mental health, or what works in tackling it. The 
challenge in collecting and mapping evidence is even greater when looking at the treatment 
gap, and their attached economic and social burden. Crucially, access to this information is 
required if policy makers are to commit greater resources to mental health care, to 
prioritise areas of greatest need, and make sensible decisions about effective and efficient 
care for mental ill-health.  Part 2 aims to examine the current state of knowledge regarding 
the impact of unmet needs associated with non-treatment in schizophrenia in OECD 
countries. We explore also how complete is the evidence available and, in case it is not 
sufficient, propose how this problem can be studied further more concretely and robustly 
and what type of data would be needed for this purpose. Findings from a systematic 
literature research are reported to map current evidence of the impact of the problem 
available from the OECD countries literature. Following we comment on the evidence 
gathered and suggest future research to fill current gaps in the evidence and to inform 
policy.  
 
Methods 
 
The search methodology was structured around the analytical framework pictured in figure 
2.  
• The focus of the search was on studies reporting on the following scenarios: missed 
or delays in diagnosis; no treatment or delays in treatment; inappropriate treatment 
(according to current care); and treatment discontinuation or drop out (non-
adherence or non-compliance pending on the terminology used in the paper).  
 
• Participants were individuals with schizophrenia (or psychosis).  
 
• The type of studies screened were literature reviews, empirical studies of 
interventions irrespective of design and observational studies. Geography included 
OECD countries.  
 
• Impact of unmet needs associated with non-treatment in schizophrenia was 
measured against the following outcomes: use of health and social care resources, 
comorbidities, use of criminal justice resources, employment, education, violence 
and premature death, and homelessness.  
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• A series of databases (MEDLINE, PsycINFO, ISI Web of Science, IBSS, and Social Care 
Online) and grey literature sources (OECD library, Open Grey library, Greylit library, 
and advanced Google search) were searched for outputs published in English 
(January 2004-September 2014).  
 
• A series of experts checked the search methodology applied, commented on the 
results of the search and provided additional evidence. Mesh terms and 
corresponding text words are fully reported in appendix 1.  
 
• The quality of the evidence was assessed against specific checklists: (Downs & Black, 
1998) for observational/clinical studies; (Mogyorosy & Smith, 2005) for cost of illness 
studies; (Drummond & Jefferson, 1996) for cost effectiveness studies; PRISMA 
guidance (http://www.prisma-statement.org/statement.htm) for literature reviews. 
 
Results 
Background results  
A total of 1017 papers were screened (811 from databases, 93 from grey literature and 43 
from experts). Of these 47 were identified as relevant for the study, see figure 3.  
• The majority of the papers reported on the impact of unmet needs on use of health 
care resources (27, 57%), violence/premature death (21, 45%) and employment 
(productivity, absenteeism; 13, 28%).   
 
• A few papers commented on use of criminal justice resources (4, 9%), education (4, 
9%), homelessness (3, 6%) or comorbidities (3, 6%).  
Mapping of the evidence according to country settings is reported in table 1.  
• The overall quality of the findings for observational studies in community (1) and 
clinical settings (24) as well as for RCT (2), cost-effectiveness models (4) and 
systematic reviews (7) was good.  
• For the narrative reviews (7) and grey literature reporting (2) the quality of the 
findings used was difficult to assess as there was very limited information available 
on the sources of evidence accessed and the robustness of the modelling applied.   
A detailed table reporting on findings according to each paper analysed is reported in 
appendix 2.  
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Figure 3:  Publications included in the review and selection process applied 
(numbers) 
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Table 1 – Mapping of the evidence according to country settings 
  Outcomes 
Country setting (no. of 
papers) 
Health 
care 
Comorbidities Criminal 
justice 
Employment Education Violence 
Death 
Homelessness 
Australia (4) - - - x - x - 
Canada (2) x - - x - - - 
Croatia (1) - - - - - x - 
Denmark (2) x - - - - x - 
France (1) - - - - - - - 
Germany (3) x - - x - x - 
Greece (1) x - - x - x - 
Ireland (3) x - - x - x - 
Italy (3) x - - x - x - 
the Netherlands (2) x - - x - x - 
New Zeeland (1) x - - - - - - 
Norway (2) x - - - - x - 
Poland (1) x - - x - - - 
Portugal (2) x - - - - x - 
Slovenia (1) - - - x x - - 
Spain (3) x - - x - x - 
Sweden (4) x - - - - x - 
UK (8) x - - x - x - 
USA (11) x - x x x x x 
International (11) x x - x x x x 
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Description of the evidence according to the outcomes 
Use of health care resources 
Impact of undiagnosed psychosis on the use of health resources  
(Lim, Jacobs, Ohinmaa, Schopflocher, & Dewa, 2008).   
• In a cross-sectional study looking at a population based measure of the economic 
burden of mental illness (including schizophrenia) in Canada, (Lim et al., 2008) 
reported that the utilisation of all health care services was highest for the 
diagnosed mentally ill, lowest for the non-mentally ill, with those in the 
undiagnosed category in the middle.  
 
• The average annual medical cost per capita was C$643 for the non-mentally ill 
and C$2,515 for the diagnosed and C$1,442 for the undiagnosed (Canada, 2003 
figures). 
Impact of untreated psychosis on the use of health resources 
(Cechnicki et al., 2014; HSM Group, 2012)(Mojtabai et al., 2009).  
• (Mojtabai et al., 2009) found a substantial level of unmet need for care among 
individuals with schizophrenia both at community level and in clinical settings.  
o For example, in the United States, the Epidemiologic Catchment Area 
population study (conducted in the early 1980s) found that among 
individuals with symptoms in the past 6 months (6-month schizophrenia), 
only 57% had received some form of outpatient mental health care in this 
period: 40% from the specialty mental health sector (psychiatrists, 
psychologists, social worker, or other mental health professionals) and 
17% from the general medical sector or the human services (such as the 
clergy or non-mental health social work) (Robins & Regier, 1991).  
o From the National Comorbidity population Surveys (NCS between 1990 
and 1992; NCS-R between 2001 and 2003) it was found that at least 40% 
of individuals with actively symptomatic schizophrenia-spectrum 
disorders living in community settings in the United States have no 
consistent contact with needed services, and more than half have no 
contact with the specialty mental health treatment sector.  
o In a longitudinal study of first-contact patients with healthcare services 
(Jablensky, 2000) reported considerable variation across the 
industrialised and the developing countries in the patterns of service use 
and the unmet need for care. 
o As another example, in a clinical epidemiological study of first-admission 
psychotic disorders from the private and public inpatient facilities in the 
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USA (Mojtabai et al., 2002) only 54.6% of the 172 first-admission patients 
with a consensus diagnosis of schizophrenia had continuous medication 
visits in the 4 years following first admission (i.e., 3–6 visits per 6 months 
throughout the 4-year follow-up) and only 17.4% had continuous 
psychotherapy visits (i.e., 12–24 visits per 6 months).  
 
• Patients with untreated schizophrenia can lead to the need for much more 
resource-intensive care (including increased inpatient care/hospitalisations, 
outpatient care, and long-term care/nursing homes) than schizophrenic patients 
who are getting regular care and treatment.  
 
• In the USA (Greater Kansas City) the annual cost of untreated SMI was estimated 
to be $624 million (about $6609 per case of untreated SMI, 2010 estimates) 
(HSM Group, 2012). About 10 % of the overall costs were direct costs, or medical 
expenses associated with lack of sustained treatment (about $696 per case of 
untreated case of SMI). Direct costs included: increased inpatient 
care/hospitalisations, outpatient care, mental health organisations, and long-
term care/nursing homes. For more details please see Part 4 - case studies. 
 
• In Poland, (Cechnicki et al. 2014) found a lack of correlation between use of 
health resources (number of re-hospitalisations and duration of re-
hospitalisations) and duration of untreated psychosis (DUP).  
Impact of non-adherence to treatment on the use of health resources  
(H. Ascher-Svanum et al., 2006; Bodén, Brandt, Kieler, Andersen, & Reutfors, 2011; Higashi 
et al., 2013; Knapp, King, Pugner, & Lapuerta, 2004b; Llorca, 2008; Marcus & Olfson, 2008a; 
Novick et al., 2010; Offord, Lin, Mirski, & Wong, 2013; Sun, Liu, Christensen, & Fu, 2007) 
(Dilla, Ciudad, & Alvarez, 2013) (King et al., 2014) (Mojtabai et al., 2009) (Karve, Panish, 
Dirani, & Candrilli, 2012) (Hong, Windmeijer, Novick, Haro, & Brown, 2009) (Haddad, Brain, 
& Scott, 2014) (Sajatovic & Ross, 2009) (Weiden, Kozma, Grogg, & Locklear, 2004).  
• Epidemiological studies find that many patients virtually drop out of treatment after 
their initial contact with services and receive little mental health care in subsequent 
years (Mojtabai et al., 2009).  
 
• Clinical studies of patients in routine treatment settings indicate that the treatment 
patterns of these patients often does not meet the criteria set by evidence-based 
practice guidelines, while at least half of these patients continue to experience 
significant symptoms. The divergence from the guidelines is more pronounced with 
regard to psychosocial than medication treatments and in outpatient than in 
inpatient settings.  
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• We can identify a clear link between non-adherence and an increased risk of 
hospitalisation, use of emergency psychiatric services, longer length of hospital stay, 
and hospital costs (Higashi et al., 2013) (Dilla et al., 2013) (for examples see: Knapp 
et al., 2004; Marcus & Olfson, 2008; Ascher-Svanum et al., 2006; Bodén et al., 2011; 
Morken, Widen, & Grawe, 2008; Weiden et al., 2004). 
 
• Key evidence from Europe 
o A multi-country observational study conducted in Denmark, Italy, Portugal, 
Spain, Ireland and the UK looking at the consequences of non-adherence with 
antipsychotic medication in the outpatient treatment of schizophrenia 
showed that non-adherence was significantly associated with an increased 
risk of relapse, hospitalisation and suicide attempts (Novick et al., 2010).  
o In a multi-country RCT based in UK, Italy, Germany and the Netherlands 
looking at the impact of non-adherence to medication in patients with 
schizophrenia (King et al., 2014) showed that the effect of non-adherence 
was not statistically significantly associated with health and social care costs, 
whereas patients who reported non-adherence had significantly lower 
societal costs than those reporting adherence. 
o Findings from an international European study (Germany, Italy, Spain, France 
Denmark, Greece, Ireland/the UK, the Netherlands, and Portugal); (Hong et 
al., 2009) demonstrate the significant economic burden of relapse (highly 
correlated to non-adherence to treatment), and show such costs were mainly 
due to hospital stay.  
Costs incurred by patients who ever relapsed during three years were almost 
double to those incurred by patients who never relapsed (£14055 vs. £7417). 
61% of the cost difference was accounted for by hospital stay.  
 
• Key Evidence from USA 
o (Sun et al., 2007) estimated that the national re-hospitalisation costs related 
to antipsychotic non-adherence was $1479 million, ranging from $1392 
million to $1826 million in 2005. 
o (Offord et al., 2013) showed that early non-adherence is related to more 
hospitalisations (0.57 vs. 0.38; P < 0.01) with longer length of stay (5.0 vs. 3.0 
days; P < 0.01) and higher yearly hospitalisation costs per person ($5,850 vs. 
$4,211; P = 0.02) compared with adherent patients.  
o (Karve et al., 2012) confirm that experiencing psychiatric-related relapse 
events almost doubles the direct costs of managing patients with 
schizophrenia. The mean schizophrenia-related total medical costs per 
patient were significantly higher among patients with 2 or more psychiatric-
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related relapse events than among patients with <2 psychiatric-related 
relapse events (17,910 vs. 10,346; 2009 US$).   
Impact of non-compliance on the use of health resources   
Four separate cost-effectiveness analyses (Damen, Thuresson, Heeg, & Lothgren, 2008; 
Treur, Heeg, Moeller, Schmeding, & van Hout, 2009) (Heeg et al., 2005) (Hensen, Heeg, Lo, 
& Hout, 2010) of compliance gains on antipsychotic treatments (based on discrete event 
simulation models) were conducted in Sweden (2), UK and Germany, respectively.  
• In Sweden (Damen et al., 2008) considered two identical treatment arms except for 
percentage of compliant patients. The difference in compliance rates was varied 
from 0% to 15%, and incremental costs and effects were recorded and analysed.  
With a 5%, 10% and 15% difference in compliance rate, incremental effects 
increased to 0.021, 0.037 and 0.062, respectively, while generating cost savings of 
Swedish kronor (SEK) 31,500, SEK 62,000 and SEK 104,500, respectively (SEK9.25 = 1, 
Euro year 2007 values). On average, the model predicted that, with a 15% increase in 
compliance, 0.5 relapses were prevented, the average Positive And Negative 
Syndrome Scale (PANSS) score decreased by 3.3 points and patients spent 22 fewer 
days in hospital over 5 years. (Hensen et al., 2010) looked at the cost effectiveness of 
long-acting risperidone in Sweden and confirmed that compliance is the main driver 
of the cost effectiveness of the medicine. Similar results are reported in Germany 
(Treur et al., 2009). 
 
• In the UK (Heeg et al., 2005) developed a model to incorporate social and 
environmental factors into the decision-making process for the prescription of new 
drugs to patients. The model was used to analyse the potential benefits of improving 
compliance with medication by 20% in patients in the UK. A 20% increase in 
compliance was estimated to save £16,147 and to avoid 0.55 psychotic episodes per 
patient over 5 years. Sensitivity analysis showed that the costs savings associated 
with increased compliance are robust over a range of variations in parameters. 
 
Comorbidities 
The evidence gathered was limited to narrative reviews looking at the unmet needs in the 
management of schizophrenia (Fleischhacker et al., 2014) (Mojtabai et al., 2009) (Torres-
González et al., 2014).  
• Poor evidence is available and refers to narrative reviews commenting on the impact 
of unmet needs on comorbidities when managing schizophrenia. 
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• No economic estimates are available related to the impact of non-treating 
schizophrenia on its comorbidities.  
 
• Evidence refers to international settings (not clearly specified). 
 
• One of the most important issues is that people with schizophrenia die 15–20 years 
earlier than the general population. It is thus important not only to manage the 
symptoms of schizophrenia but also to treat coexisting physical illnesses. Under-
diagnosis and under-treatment of schizophrenia (and related comorbidities) 
contribute to this high death rate. It should be a priority to develop and implement 
an evidence-based, integrated care package that addresses patients’ mental and 
physical health needs (Fleischhacker et al., 2014). 
 
• The high prevalence of medical problems in patients with schizophrenia calls for 
integration or better coordination of mental health and general medical services.  
(Mojtabai et al., 2009) reported that in the literature there has been a renewed 
interest in the medical care of these patients, including receipt of the needed 
preventive and treatment services for chronic medical conditions and dental care.  
 
• In a more recent review (Torres-González et al., 2014) confirmed that, in 
schizophrenia, an increased likelihood risk for overweight, obesity, and abdominal 
obesity is present even in recently diagnosed and non-treated patients. However no 
economic estimates are available related to the impact of non-treating schizophrenia 
on its comorbidities.  
 
Use of criminal justice resources 
• Only four papers were identified as suitable for analysis (H Ascher-Svanum et al., 
2006; HSM Group, 2012; Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) 
(Haddad et al., 2014); these studies included one observational study, one economic 
modelling and two narrative reviews/reports.  
• The setting was limited to the USA. Comparison included: untreated psychosis (2), 
and non-adherence to treatment (2). 
 
Impact of untreated psychosis on the use of criminal justice resources  
It is recognised that the costs of mental disorders are more indirect than direct, and they are 
primarily related to a lack of treatment.   
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• Two papers looking at the cost of non-treating mental illness in the USA (Greater 
Kansas City Area, Missouri  (HSM Group, 2012) and Houston, Texas (Schnapp WB, 
Burruss JW, Hickey S, Mortesen K, 2009)) reported on the indirect costs of mental 
health disorders, including the costs of lost productivity due not only to morbidity 
and premature deaths (mortality costs), but also other factors such as incarceration.  
• In Greater Kansas City, the annual incarceration costs of individuals with severe 
mental illness resulted in $8.2 million to the criminal justice system (2010 estimates, 
(HSM Group, 2012)).  For the Harris County, Texas, the 2008 costs of caring for the 
County’s incarcerated people with mental illness exceeded $48 million (Schnapp WB, 
Burruss JW, Hickey S, Mortesen K, 2009).  
• The annual costs for the criminal justice system per case of untreated severe mental 
illness are US$87 (2010; greater Kansas City Area, USA; HSM Group, 2012).  
 
Impact of non-adherence to psychotic treatment on the use of criminal 
justice resources  
• In their literature review (Haddad et al., 2014) reported on the association 
between antipsychotic non-adherence and a significantly higher rate of 
psychiatric hospitalisation, use of emergency psychiatric services, arrest, 
violence, victimisation, and substance use plus poorer mental functioning, poorer 
life satisfaction, and more alcohol-related problems.  
 
• Non-adherence is associated with poorer functional outcomes, including greater 
risks of psychiatric hospitalisations, use of emergency psychiatric services, as well 
as arrests, violence, victimisations, poorer mental functioning, poorer life 
satisfaction, greater substance use, and more alcohol-related problems (all p < 
0.01; (H Ascher-Svanum et al., 2006)).  
 
Employment (productivity, absenteeism) 
Thirteen publications were identified suitable for analysis (Cechnicki et al., 2014; Higashi et 
al., 2013; Hill et al., 2012; HSM Group, 2012; Lim et al., 2008; Llorca, 2008; Norman et al., 
2012; OECD, 2014; Reininghaus et al., 2008; Šarotar, Pesek, Agius, Pregelj, & Kocmur, 2008; 
Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) (Schimmelmann et al., 2008) (Hong et 
al., 2009).  
• They included: observational studies (8), narrative reviews/reports (3), and 
systematic literature reviews (2).  
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• International settings covered:  USA (2), Ireland (2), UK (2), Australia (1), Canada (1), 
Poland (1), Slovenia (1), Germany (1), Italy (1), Spain (1), Portugal (1), France (1), 
Denmark (1), Greece (1), the Netherlands (1), International literature (not specified, 
2).  
 
• Comparison included:  undiagnosed psychosis (1), untreated psychosis (8), non-
adherence to psychotic treatment (2), and non-compliance (1).  
Impact of undiagnosed psychosis on employment  
• In a population based cross sectional study in Canada (Lim et al., 2008) reported that 
absenteeism (long-term work loss) is highest for the diagnosed mentally ill, lowest 
for the non-mentally ill, with those in the undiagnosed category in the middle. 
Unemployment rate is highest for the diagnosed 0.46%, but a smaller group of 
undiagnosed (0.26%) were unemployed compared with people with no mental 
illness (0.33%). The number of disability days per year (short-term work loss) were, 
respectively:  33 (diagnosed mentally ill), 27 (undiagnosed mentally ill), and 10 (non-
mentally ill).  
 
• The value of work loss from absenteeism was about 10% higher than the value of 
work loss from unemployment; and together they account for about 35% of the 
burden.  
 
• The monetary value of work loss (due to both absenteeism and disability loss) was 
14,110 C$ for the diagnosed compared with 3619 C$ for the undiagnosed (annual 
total burden of 17729 C$; (Canada, 2003 figures; Lim et al., 2008)). 
 
Impact of untreated psychosis on employment  
(Cechnicki et al., 2014; HSM Group, 2012; Norman et al., 2012; OECD, 2014; Reininghaus et 
al., 2008; Šarotar et al., 2008; Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) 
(Schimmelmann et al., 2008).   
• Mental illnesses have a huge labour market cost: OECD data suggests that one in five 
working age people have had a mental problem at some point in time, reducing their 
employment prospects, productivity and wages (OECD, 2014).  
 
• The high costs of mental illnesses (including untreated mental illnesses) for society 
suggest a strong need for better services. They have been shown to have a strong 
relationship with higher unemployment, higher absenteeism, lower productivity in 
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the workplace, and a rising burden of disability benefits claims across countries 
(OECD, 2014). 
 
• Two studies looked at the cost of non-treating mental illness in the USA (Greater 
Kansas City Area, Missouri  (HSM Group, 2012), and Houston, Texas (Schnapp WB, 
Burruss JW, Hickey S, Mortesen K, 2009)) and reported on the impact of untreated 
psychosis on employment and productivity. When modelling the cost of non-treating 
mental illness in Greater Kansas City Area, USA (HSM Group, 2012) it is reported that  
overall about 24% of individuals with SMI are unemployed at any given time, and 
about half of those cases are due to lack of treatment. In Greater Kansas City, this 
can lead to more than 15,000 adults who are unemployed due to lack of treatment 
for SMI. A high proportion (88%) of the total burden of untreated SMI (including 
schizophrenia) was in the form of indirect costs to employers and individuals. The 
annual indirect costs (absenteeism, presenteeism, unemployment, premature death) 
per case of untreated SMI are US$5785 (2010). 
 
• When looking at the consequences of untreated mental illness in Houston (Texas, 
USA) an insufficiently funded mental health service is reported to lead to societal 
productivity loss, homelessness, increased juvenile and adult criminal justice system 
involvement and decrease in life expectancy (Schnapp WB, Burruss JW, Hickey S, 
Mortesen K, 2009).  
 
• Delay in treatment with antipsychotic medication (duration of untreated psychosis, 
DUP) was found to be allocated with unfavourable course of schizophrenia, including 
negative occupational functioning and disability benefit. In Poland (Cechnicki et al., 
2014) analysed the relationship between the duration of DUP and the course of 
schizophrenia in a 20-year follow up study. In terms of employment, the relationship 
between longer DUP and worse employment outcome was statistically significant at 
7 and 12 years from first hospitalisation. In Slovenia (Šarotar et al., 2008) showed 
that half of the patients with DUP longer than 1 year were on disability benefit as 
compared to 19% of patients who had received treatment with antipsychotic 
medication in the prodromal phase of the disease.  In Canada (Norman et al., 2012) 
found that delay between onset of non-specific symptoms and treatment (duration 
of untreated illness, DUI) was a more robust predictor of occupational functioning 
and use of a disability pension compared with DUP. In Australia (Schimmelmann et 
al., 2008) in a longitudinal study involving 786 patients with first-episode psychosis 
(FEP) showed that  duration of untreated psychosis is associated with a lower rate of 
employment/occupation (p<0.01). In the UK (Reininghaus et al., 2008) confirmed 
association between untreated psychosis and unemployment; unemployed subjects 
were more likely to experience longer periods of untreated psychosis when 
Cost and impact of non-treating severe mental illnesses (SMIs):  
The case study of schizophrenia                                                                      
 
 
35 
 
reporting low (P < 0.01) or medium (P < 0.01) number of social contacts. No such 
difference could be observed for those with high social contacts (P = 0.60). 
 
Impact of non-adherence/non–compliance to psychotic treatment on 
employment 
• Systematic review of the international literature showed that non-adherence, partial 
adherence and non-compliance can arise a downward spiral of events leading to 
inconsistent symptom control, relapse and re-hospitalisation, which in turn can lead 
to long-term functional disabilities, and loss of employment possibilities (Higashi et 
al., 2013) (Llorca, 2008).  
 
• Findings from the large prospective pan-European Schizophrenia Outpatient Health 
Outcomes (SOHO) study show that relapsers had an earlier onset of schizophrenia 
and had a poorer level of social functioning at baseline (i.e. a lower frequency of paid 
employment and social contacts in previous 4 weeks) compared with individuals who 
never relapsed (Hong et al., 2009). (Hill et al., 2012) reported no association between 
DUP and gainful employment over 12 years. 
 
Education 
Four papers were identified suitable for analysis (Šarotar et al., 2008; Schnapp WB, Burruss 
JW, Hickey S, Mortesen K, 2009) (Higashi et al., 2013; Llorca, 2008), including observational 
studies (2), systematic literature reviews (2), and one narrative review (1).  
• International settings covered: USA (1), Ireland (1), Slovenia (1), International 
literature (not specified, 2).  
 
• Comparison included: untreated psychosis (2), non-adherence to psychotic 
treatment (1), and non-compliance (1).  
 
Impact of untreated psychosis on education 
(Šarotar et al., 2008; Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009).  
• Evidence from the USA showed that untreated subjects often have difficulty in 
school and have an increased likelihood of becoming involved with the juvenile 
justice system (Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009).   
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• In Slovenia (Šarotar et al., 2008) found that DUP longer than 1 year had a negative 
impact on the educational level achieved. 
 
Impact of non-adherence to psychotic treatment on education 
There is evidence in the literature to say that non-adherence, partial adherence and non-
compliance can lead to loss of education (systematic reviews conducted by (Higashi et al., 
2013; Llorca, 2008). 
 
Violence and premature death  
Twenty-one papers were identified suitable for analysis, including observational studies 
(11), literature reviews/meta-analysis (7), and one RCT, one model and one report. 
(Nielssen, Malhi, McGorry, & Large, 2012) (Challis, Nielssen, Harris, & Large, 2013) (OECD, 
2014) (Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) (HSM Group, 2012) (Nielssen 
& Large, 2011) (Mork et al., 2013) (Nielssen & Large, 2009) (Yee, Large, Kemp, & Nielssen, 
2011) (Arango, Bombín, González-Salvador, García-Cabeza, & Bobes, 2006) (Foley et al., 
2007) (Higashi et al., 2013) (Novick et al., 2010) (Llorca, 2008) (Fazel, Buxrud, Ruchkin, & 
Grann, 2010) (H Ascher-Svanum et al., 2006) (Fazel, Zetterqvist, Larsson, Långström, & 
Lichtenstein, 2014; Hong et al., 2009; Kudumija Slijepcevic et al., 2014; Látalová, 2014; 
Mojtabai et al., 2009). 
• International settings covered:  USA (5), Australia (3), Ireland (2), Denmark (2), 
Sweden (2), Norway (1), Italy (2), Portugal (2), Spain (3), UK (2), Ireland (1), the 
Netherlands (1), Slovenia (1), Croatia (1), Germany (1), France (1), Greece (1), 
International literature (not specified, 6).  
 
• Comparison included:  untreated psychosis (10), non-adherence to psychotic 
treatment (9), and non-compliance (2). 
 
• The majority of the evidence describes the social impact of unmet needs 
looking at prevalence of violent acts (self-harm or aggressive behaviour towards 
others), suicide attempt or criminal offences (due to violent acts and 
homicides). 
 
• A recent OECD report (2014) described that psychiatric illness is a major risk factor 
for suicide and it has been estimated that 90% of suicide attempters and completers 
suffer from at least one, mostly unrecognised, untreated, or inadequately treated 
mental illness. 
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Impact of untreated psychosis on violence and premature death  
(Nielssen et al., 2012) (Challis, Nielssen, Harris, & Large, 2013) (OECD, 2014) (Schnapp WB, 
Burruss JW, Hickey S, Mortesen K, 2009) (HSM Group, 2012) (Nielssen & Large, 2011) (Mork 
et al., 2013) (Nielssen & Large, 2009) (Kudumija Slijepcevic et al., 2014; Látalová, 2014). 
• Violent behaviour frequently develops before the onset of a first episode. Available 
evidence suggests that the prevalence of violent behaviour in the first episode of 
psychosis, particularly schizophrenia, is greater than during the later stages of the 
illness. First-episode psychosis is associated with an increased risk of homicide. There 
is some limited evidence for an effect of DUP length on serious violence or 
aggression (Látalová, 2014).  
 
• A review of the evidence on violence acts to self and others during the first episode 
of psychosis showed that a substantial proportion of first-episode patients commit 
an act of less serious violence or attempt suicide prior to initial treatment (Nielssen 
et al., 2012).  
 
• In a systematic meta-analysis of the risk factors for deliberate self-harm before and 
after treatment for first-episode psychosis (Challis, Nielssen, Harris, & Large, 2013) 
reported that DUP is associated with an increased risk of deliberate self-harm.  
 
• In Croatia (Kudumija Slijepcevic et al., 2014) reported that DUP before first contact 
with psychiatric services acts as one of the predictors of violence, together with 
older age and alcohol abuse.  
 
• In the USA, over 15 percent of indirect costs of severe mental illness (treated and 
untreated cases) are related to mortality costs, or loss of productivity due to 
premature death (Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009).  
 
• The annual cost burden of untreated SMI in the USA (Greater Kansas City) has been 
estimated to be $624 million (2010 estimates, (HSM Group, 2012)). A high 
proportion, 87.5%, of these costs is in the form of indirect costs to employers and 
individuals, including unrealised earnings due to permanent disability or premature 
death (suicides). The model estimated that 67 suicides in Greater Kansas City can be 
attributed to SMI annually (HSM Group, 2012).  
 
• Psychosis is strongly associated with potentially lethal suicide attempts using sharp 
objects and patients who have never received treatment for psychosis appear to be 
at particular risk (Nielssen & Large, 2011).  
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• When compared with non-suicide attempters and those with suicide attempts 
without non-suicidal self-harm, patients with both suicide attempts and non-suicidal 
self-harm were more frequently women, younger at the onset of psychotic 
symptoms, had longer duration of untreated psychosis, and had higher levels of 
current impulsivity/aggression and depression (Norway, (Mork et al., 2013)).  
 
• When looking at untreated psychotic illness in the survivors of violent suicide 
attempts, there appears to be a higher risk of violent suicide attempts during the 
first episode of psychosis than later in the illness (Nielssen & Large, 2009). 
Impact of non-adherence to psychotic treatment on violence and premature 
death  
(H Ascher-Svanum et al., 2006) (Yee et al., 2011) (Arango et al., 2006) (Foley et al., 2007) 
(Higashi et al., 2013) (Novick et al., 2010) (Fazel et al., 2014; Hong et al., 2009) (Haddad et 
al., 2014). 
• Good adherence to treatment appears to be associated with lower levels of 
aggressive behaviours and people with schizophrenia who adhere to their treatment 
and are clinically stable appear to be no more violent than the general population 
(Fleischhacker et al., 2014). 
o In the USA when observing medication adherence in the treatment of 
schizophrenia in usual care, lack of adherence was associated with poorer 
outcomes, including increased acts of violence (H Ascher-Svanum et al., 2006) 
(Haddad et al., 2014).  
 
o In Australia, when looking at severe non-lethal violence during psychotic 
illness, individuals who committed a severe violent offence were typically 
non-adherent to treatment, had co-morbid substance use and prior criminal 
convictions (Yee et al., 2011).  
 
o In Europe (Hong et al., 2009) showed that more relapsers (5.8%) had suicide 
attempts in the six months before baseline, compared to non-relapsers 
(3.3%). For other examples please refer to (Fazel et al., 2014) (Arango et al., 
2006).  
 
o In contrast with the evidence reported above, (Foley et al., 2007)  did not find 
an association between violence at presentation and DUP. They argued that 
the relationships between violence, DUP and psychopathology may be 
confounded by other methodological factors such as potential difficulties 
inherent in the completion of outcome measures used in the study (see the 
Positive and Negative Syndrome Scale PANSS). 
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• Suicide is one of the leading causes of premature death in patients with 
schizophrenia, but it is highly preventable. Evidence reported in a systematic review 
literature showed that non-adherence to antipsychotic medication is one of the risk 
factors for the development of suicidal behaviour in patients with schizophrenia 
(Higashi et al., 2013).  
o An international study conducted in Denmark, Italy, Portugal, Spain, Ireland 
and the UK showed how non-adherence is significantly associated with an 
increased risk of suicide attempts (Novick et al., 2010). 
Impact of non-compliance to psychotic treatment on violence and premature 
death  
(Llorca, 2008) (Fazel et al., 2010). 
• It is commonly recognised in the literature that non and partial compliance can 
lead to long-term negative outcomes (loss of autonomy, education or 
employment possibilities, homelessness, a likelihood of dropping out of care 
completely) and even suicide (Llorca, 2008).  
 
• When looking at homicide in discharged patients with schizophrenia and other 
psychoses in Sweden, common factors associated with homicide were 
evidence of medication non-compliance and substance misuse (Fazel et al., 
2010). 
 
Homelessness 
Three reviews of the literature were suitable for analysis, two narratives on the USA 
(Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) (Mojtabai et al., 2009), and one 
systematic review on international settings (Llorca, 2008).  
Limited evidence describes the economic impact of unmet needs looking at the use of 
healthcare resources (e.g. hospitalisation, emergency services) and housing costs. 
Impact of untreated psychosis on homelessness  
• Many patients with schizophrenia are at increased risk of homelessness and 
associated adverse social and health outcomes, such as victimisation and sexually 
transmitted diseases (Mojtabai et al., 2009).  
 
• People with schizophrenia and other severe mental illnesses who become homeless 
have difficulty accessing healthcare. The lack of a permanent address, complicated 
eligibility requirements and daily struggles with their untreated mental illness are 
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barriers to accessing primary care. This ultimately leads to use of higher-cost services 
such as emergency departments and inpatient care (Schnapp WB, Burruss JW, 
Hickey S, Mortesen K, 2009).  
 
• The cost of providing permanent, supportive housing for people with severe mental 
illness may be offset by savings incurred by reductions in healthcare costs in public 
hospitals, and also in prisons, and shelter systems (Schnapp WB, Burruss JW, Hickey 
S, Mortesen K, 2009).  
Impact of non-compliance to psychotic treatment on homelessness - Non- and 
partial compliance can lead to long-term negative outcomes including homelessness (with a 
high likelihood of dropping out of care completely) (Llorca, 2008). 
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• Results from the search of the literature reveal considerable gaps in our current 
knowledge on the extent of the unmet need for care.   
 
• The majority of the evidence is limited to delays in or missed treatment in hospital 
settings, whilst very little is known on unmet needs at earlier (diagnosis) or later 
(community treatment) stages of the patient pathway. 
 
• The majority of the evidence describes the impact on healthcare resource use, 
violence or employment whilst less attention is paid to homelessness and use of 
criminal justice resources outcomes. 
 
o Limitations due to the choice of sample - difficulties in reaching particular 
groups of the population in need – e.g. homelessness, prisoners or younger 
individuals. 
 
o Future research is needed to address unmet needs across settings. 
Retrospective data collection of patient level data from first-episode patients 
in contact with mental health services, primary care social care services could 
allow having broad-spectrum information on the impact of non-treatment on 
multiple outcome measures. 
 
• The majority of the evidence identifies unmet needs in clinical setting.   
 
o Limitations: there is a lack of reliable data from population-based 
epidemiological studies on which to base the population estimates of 
treatment and the potential unmet need for treatment. 
 
o Future research could benefit from ongoing country specific national surveys 
to source information on the impact of non-treatment on multiple outcomes. 
For example one of the current English National surveys (such as LHA 
National Survey of Health and Development) could act as a useful source of 
KEY MESSAGES AND 
OPPORTUNITIES FOR FUTURE 
RESEARCH 
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information on the impact of non-treatment on multiple outcomes (e.g. 
access and use of health and social care resources, employment, education).  
 
This is a cohort of 5,362 births in 1946 followed up to the present day. It 
contains data on subjects' physical and mental health, including 
observational measures, diet and lifestyle, and family, employment and social 
circumstances. It would allow comparing people with a diagnosis of mental 
health illness vs individuals who self-reported a mental health problem but 
were not diagnosed/never received treatment for their mental health issue. 
Individuals could be followed longitudinally until their older life to capture 
the impact of childhood determinants (or delays in treatment) on access to 
resources in adulthood and older stages. 
 
• Poor evidence on the impact of unmet needs on physical comorbidities. 
 
o Limitations: recognition and management of comorbidities in people with 
schizophrenia are made more difficult by barriers related to the patients, the 
attitudes of medical practitioners, and the structure of healthcare delivery 
services.  
 
o Future research should produce economic and social estimates related to the 
impact of non-treating schizophrenia on its comorbidities. 
 
• Discrepancy of evidence across settings, few countries (e.g. USA, UK) present 
stronger evidence than others.  
 
o Limitations: discrepancies across settings in the information system that 
support the management of care and access to data on the diagnosis, care 
and treatment gap of schizophrenia.  
 
o Future research: the data base of evidence gathered here could be used to 
inform a future modelling exercise to predict the impact of non-treatment 
across multiple scenarios and settings. 
  
Cost and impact of non-treating severe mental illnesses (SMIs):  
The case study of schizophrenia                                                                      
 
 
43 
 
PART 3 - CHALLENGES AND FUTURE 
OPPORTUNITIES  
 
Improving care for people with schizophrenia, their caregivers, and their families is an 
urgent health care priority across country settings (OECD, 2014).  
Although schizophrenia is a disabling and severe mental disorder, people with the illness 
can, when supported by appropriate diagnosis, assessment, management, recognition and 
support of their needs, report a positive impact on their health which can lead to recovery 
(Fleischhacker et al., 2014).   
Unfortunately the social and economic costs of neglecting mental healthcare are a major 
problem and three public health initiatives are suggested by OECD to respond better to the 
growing urgency of poor mental health (OECD, 2014). They include: Measuring mental 
health to better understand the scale of the problem, and what works in tackling it; 
Increasing provision of evidence-based services, especially through expanding the role of 
the primary care sector, with appropriate system-wide support; Securing better outcomes 
for mental disorders through greater use of incentives.  
The objectives of part 3 of the report are to: discuss what the policy issues and policy gaps 
are in connection with non-treatment; and propose possible solutions on how to address 
those gaps identified.  
Firstly, evidence from the literature is used to define possible issues and opportunities when 
dealing with the problem. Following that, comments from a group of leading experts 
(including researchers and practitioners) in the field of schizophrenia/psychoses are 
presented to shape recommendation to policy on the issues to be prioritised and their 
possible solutions. 
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Source of the problem 
 
Evidence from the literature report on the following reasons for unmet needs: 
patient/caregiver factors; provider factors; and health care system factors.  
 
Patient/caregiver factors 
• Lack of illness awareness - Patients and their family members do not recognise that 
they/their relatives have symptoms. They may focus instead on various somatic 
concerns, such as gastrointestinal complaints, fatigability, and headaches. Others 
may recognise that there is a problem, but fail to identify it as schizophrenia. 
(Hirschfeld et al., 1997) (Statistics, 2012) (Cooke, 2014).  
 
• The direct impact of symptoms – They cover depression, cognitive impairment, 
positive and negative symptoms. Few examples include: auditory hallucinations that 
may instruct the patient not to take the medication; withdrawal/lack of ability to 
begin and sustain planned activities such as taking the medication; or poor ability to 
understand information on their care and use it to make decisions (Haddad et al., 
2014) (Statistics, 2012). 
 
• Lack of severity awareness - Patients and their family members underestimate the 
severity of the problem, they do not see the psychotic episode as serious enough to 
seek treatment (Hirschfeld et al., 1997) (Statistics, 2012).  
 
• Limited access to treatment - Patients and their family members who do recognise 
or acknowledge that they need help may face limited access to treatment (Hirschfeld 
et al., 1997) (Statistics, 2012). 
 
• Lack of awareness of the time course for symptom improvement - Patients may not 
be aware of the time course for symptom improvement after starting antipsychotic 
medication and do not discuss switching to another antipsychotic, if they do not 
respond to an adequate trial of a medication (Haddad et al., 2014). 
 
• Lack of knowledge about side effects of medications - It is important that patients 
are warned of side effects before starting medication. For example increasing the 
dose gradually and/or explaining to the patient that side effects should settle can 
reduce the likelihood of side effects impairing adherence. Managing side effects that 
emerge during treatment depends on their detection in liaison with the healthcare 
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providers. The use of a simple checklist can also aid the detection of side effects 
(Haddad et al., 2014).  
 
• Lack of skills or management strategies to cope with side effects – The impact of 
side effects can sometimes be reduced in liaison with the healthcare provider, by 
altering the timing of medication-taking. For example, if clozapine is causing 
sedation, the greater part of the dose can be taken at night-time rather than splitting 
the dose equally between morning and night-time. Other strategies to manage side 
effects include dose reduction, recommending a specific treatment for a side effect 
(e.g. weight management program for antipsychotic-associated weight gain), 
prescribing another medication (e.g. an anticholinergic drug to treat antipsychotic-
induced Parkinsonism), or switching to another antipsychotic (Haddad et al., 2014).  
 
• Stigma and negative perceptions about psychiatric care and schizophrenia  - Even 
when treatment for schizophrenia is readily available patients are sometimes 
reluctant to seek psychiatric care because they fear prejudice and discrimination 
(Statistics, 2012) (Fleischhacker et al., 2014). 
 
• Monetary costs to the patients and their families - They have to bear the financial 
expenses associated with mental health treatment and care (Doessel et al., 2010) 
(Statistics, 2012). 
 
• Lack of support from family/caregivers to remind patients to take the medications 
- Although professional support can be helpful, often the most important source of 
help and support in the management of the disease is the network of relationships: 
friends, family and community (Cooke, 2014). For example, they can offer to 
accompany the friend or relative to appointments, or help them when taking 
medications. One aspect of non-adherence to medication can be viewed as lack of 
capacities within the family to remind patients to take their medication (Haddad et 
al., 2014).  
 
Provider factors   
• Lack of appropriate information, training and education on schizophrenia - Reasons 
that rest with the primary care providers include the failure of medical schools in 
providing appropriate education about psychiatric diagnosis, psychopharmacology, 
or psychotherapy for schizophrenia (Fleischhacker et al., 2014) (Haddad et al., 2014). 
 
• The believe that schizophrenia is not a "real" illness - Primary care providers may 
believe that psychiatric disorders are not "real" illnesses compared with other 
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physical illnesses with tangible biomarkers that can assist in the assessment of risk, diagnosis 
and monitoring of their progression (Doessel et al., 2010) (Cooke A, 2014).  
 
• Lack of training in interpersonal skills - Primary care providers may have limited 
training in the interpersonal skills that enable them to manage emotional distress 
people and therefore they prefer to avoid dealing with these patients (Haddad et al., 
2014). Emotional support and help with practical issues is often as important as help 
targeted directly at ‘symptoms’ (Cooke, 2014). 
 
• Poor quality of communication and collaboration between the providers and the 
patients in care management - There is a lack of alliance with patients and their 
families to ensure that recommendations on treatment goals and strategies are met 
(Fleischhacker et al., 2014) (Statistics, 2012). A useful role for professionals is helping 
friends, family and self-help groups to support people in needs (Cooke, 2014). 
 
• Care plan limitations - Managed care plans can make it difficult for physicians to 
prescribe newer medications, even though they are now widely regarded as safer 
first-line treatments. Managed care procedures can also inhibit appropriate referral 
to a psychiatrist (Hirschfeld et al., 1997). 
 
• Lack of continuity of care with a single clinician - Extensive evidence exists that 
initiatives designed to improve continuity of care can produce a favourable outcome 
in schizophrenia care (Haddad et al., 2014) (Fleischhacker et al., 2014). 
 
• The attention is on other phenomena - that have become medicalised - see sadness 
and general stress of everyday life as commented by (Doessel et al., 2010). 
 
• Social and cultural factors - (Fleischhacker et al., 2014) (Statistics, 2012) report that 
social and cultural factors can either increase or decrease adherence. There is also 
huge diversity in the way that experiences are understood (and treated) in different 
cultures. In some cultures, experiences such as hearing voices are highly valued as 
spiritual gifts (Cooke, 2014). 
 
Health care system factors  
• Difficulties in providing the appropriate service – e.g. providers who have been 
trained specifically in these modalities are not readily found in some 
communities/primary care premises (Hirschfeld et al., 1997) (Fleischhacker et al., 
2014).  
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• Poor collaboration among the different parties - Lack of integrated team approach, 
involving psychiatrists, a range of health care professionals, social care providers, 
and other external agencies. It also involves collaboration with people with 
schizophrenia, their families, and other sources of support (Fleischhacker et al., 
2014). 
 
• Lack of adequate insurance reimbursement for services - For private health care 
systems, such a team approach will require careful alignment of reimbursement 
mechanisms to support high-quality care (Statistics, 2012) (Fleischhacker et al., 
2014). 
 
• Lack of monitoring of patients - The system discourages the proper monitoring of 
patients once the treatment regimen is started. For example, see patients who need 
to be re-evaluated at frequent intervals, to assess whether the treatment is working 
in a reasonable amount of time and to give the provider the opportunity to make 
adjustments in the treatment regimen (Haddad et al., 2014). 
 
Challenges in the evaluation of the impact 
 
Multiple challenges have been identified in the literature when dealing with the social and 
economic impact of untreated schizophrenia. The most recurrent include: 
• Discrepancies in the information system that supports the management of care – 
There is evidence that shows how electronic records have potential to improve 
medication management for patients in mental health centres over traditional 
records. However, medication documentation for patients diagnosed with 
schizophrenia can be deficient in many areas, regardless of documentation format 
(Tsai & Bond, 2008) (OECD, 2014).  
 
• Discrepancies between different criteria used for the assessment and diagnosis of 
schizophrenia - There are diagnostic discrepancies due to cultural differences and 
they refer to different characteristics of patients and clinical presentation of the 
illness in different countries, as well as to different interpretation of the psychiatrists 
due to their personal and professional experience, their personal training and the 
environment where they work (Rezvyy, Oiesvold, Parniakov, & Olstad, 2005). Over 
time, the list of psychiatric diagnoses has expanded to a point that some have 
argued that the list is now so exhaustive that we would all fit one category or 
another. The newest version of the diagnostic manual, DSM 5, has been so 
controversial (Cooke, 2014). 
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• Discrepancies in methods used when assessing non-adherence/ non-compliance - 
Multiple methods have been used in research studies to quantify adherence, and the 
choice of method greatly impacts the finding (Haddad et al., 2014)(Sajatovic & Ross, 
2009).  
 
• Choice of sample – researchers may experience difficulties in reaching particular 
groups of the population in need – e.g. homeless people, prisoners, or younger 
groups (Mojtabai et al., 2009). 
 
What can be done to address the problem 
 
• Providing educational programs to increase provider knowledge and 
understanding about schizophrenia - Ensure that enough medical professionals are 
expertly trained to perform detailed assessment and diagnosis in patients with 
suspected schizophrenia. Train junior doctors in thorough clinical assessment, 
accurate diagnosis, and good prescribing practice (Fleischhacker et al., 2014). 
Professionals need to shift from seeing themselves as treating disease to seeing 
themselves as providing skilled help and support to people who are experiencing 
understandable distress (Cooke, 2014). 
 
• Increasing patient, caregivers/family and society knowledge and understanding 
about schizophrenia - (Fleischhacker et al., 2014) highlight the needs of concrete 
support, information, and educational programs to families and caregivers on how to 
enhance care for an individual living with schizophrenia in a manner that entails 
minimal disruption to their lives. Campaigns to increase awareness and tackle 
prejudice and discrimination toward people with schizophrenia can be effective in 
diminishing negative attitude. 
 
• Enhancing the role of patients and their families in decision making for patient care 
- WHO Global Mental Health Action Plan (World Health Organization, 2013), which 
emphasizes the use of evidence-based therapies and the empowerment of people 
with mental disorders. (Fleischhacker et al., 2014) report how patient empowerment 
constitutes a significant factor in achieving recovery. The British Psychological 
Society says that it should be standard practice for service users to be involved at all 
levels, from planning the service as a whole to providing feedback to individual 
teams and, perhaps most importantly, in planning their own care (Cooke, 2014). 
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• Developing performance standards for behavioural health care -The limitations of 
current care are such that the UK Schizophrenia Commission has labelled 
schizophrenia “the abandoned illness” (The Schizophrenia Commission, 2012). It is 
therefore imperative that our existing (and effective) tools are available to all those 
with schizophrenia who need them; our best practices should become standard and 
monitored using appropriate performance indicators. There is good evidence that 
high-quality, early intervention services increase the likelihood of a good outcome 
and are cost-effective (Fleischhacker et al., 2014). 
 
• Providing care treatment guidelines and protocols accessible to patients and 
providers -  (Fleischhacker et al., 2014) invite practitioners and policy makers to 
provide an evidence-based, integrated care guidance for people with schizophrenia 
that addresses their mental and physical health needs. Such recommendations 
should be agreed jointly by health care providers and people with schizophrenia (or 
their representative if appropriate). National and international psychiatric 
organizations should work together to develop and implement consistent guidance 
for good prescribing practice (Hirschfeld et al., 1997).  
 
• Supporting more effective collaboration among primary care providers, 
psychiatrists, and other mental health professionals - (Fleischhacker et al., 2014)  
say that all stakeholders, including organisations that support people living with 
schizophrenia, should be consulted to regularly revise, update, and improve policy 
on the management of schizophrenia. An integrated approach, delivered by a 
multidisciplinary team working with the patients and their families, can significantly 
improve the outcome of schizophrenia treatment and coexisting physical illness.  
 
• Promoting the use of tools to remember daily medication doses - There is 
increasing interest in electronic reminders and monitoring systems to enhance 
adherence (e.g. see “Short Message Service” text messaging and real-time 
medication monitoring linked to smart pill containers or an electronic ingestible 
event marker; Haddad, Brain, & Scott, 2014). 
 
• Ensuring that services are easily accessible by patients - The provision of adequate 
measures to decrease the burden of illness requires effective coordination of 
services, their accessibility and continuity of health and social care (Fleischhacker et 
al., 2014).  Service structures need to allow providers the flexibility to tailor help to 
the particular needs of each person rather than offering standardised packages of 
care (Cooke, 2014).  
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Challenges and opportunities in addressing 
the problem: the experts’ view  
Objectives and methods 
The data reported here were collected through a web-based survey designed to assess 
international experts' perceptions of unmet needs in schizophrenia. In particular we aimed 
at collecting their feedback on what the policy issues and policy gaps are in connection with 
non-treatment; and possible solutions on how to address those gaps. The survey was 
conducted by the London School of Economics in collaboration with a team of international 
experts in schizophrenia who supported its dissemination to international colleagues. A 
snowball sampling approach was used and replies were collected between December 2014 
and January 2015. Subjects were contacted by email in a two-step process, including initial 
contact and one reminder at two-week intervals. Given the limited resources and time 
constraints the goal of the project was to get opinions from a series of high-profile 
international experts rather than a representative sample of mental health 
professionals/researchers based in particular country settings.  
A series of 5-point Likert questions (strongly disagree, disagree, unsure, agree, strongly 
agree) were used to examine the above objectives and they are detailed in each relevant 
findings section. In brief, however, we relied upon two relevant question sets:  
• Challenges in addressing the non-treatment of schizophrenia (including 
patient/caregiver, provider health care system and evaluation of the impact factors);  
• Opportunities in addressing the non-treatment of schizophrenia.  
• Additional information was collected on the country of residence and on the 
personal academic and professional experience of the expert (number of years and 
field of research/practice).  
Responses were anonymised and the frequency of responses to questions was analysed 
using SPSS software. Data were analysed for the whole study population. 
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Results: survey responses 
Responses in time for analysis for this reporting arrived from 25 experts (13.7%; 25/183) 
from Germany (5),  USA (4), Spain (3), Italy (2), Austria (1), England (1), Finland (1), Greece 
(1), Hungary (1), Denmark (1), Poland (1), South Africa (1), Latvia (1), Bulgaria (1), 
Montenegro (1).  
Almost all of them (96%; 24/25) reported research experience (average of 20 years) in  the 
field of schizophrenia, suicide, psychiatry, social neuroscience, clinical psychology, 
depression/anxiety. 88% (22/25) had also clinical experience (average of 23 years) in clinical 
psychology and psychiatry/psychotherapy. 
 
Results: expert feedback on the source of the problem 
 
Barriers to change: patient and caregiver factors 
The majority of the experts stated they strongly agreed/agreed (%) with the following: 
• Stigma and negative perceptions about psychiatric care and schizophrenia (Stigma 
and negative perceptions about psychiatric treatment (100%); being reluctant to see 
a psychiatrist or other mental health care specialist (95.9%); 
 
• The direct impact of symptoms (suffering from psychotic symptoms (87.5%) or 
cognitive impairment (83.3%); 
 
• Lack of knowledge about side effects of medications (66.7% ); 
 
• Lack of skills or management strategies to cope with side effects (62.5%); 
 
• Lack of illness awareness/not knowing what to do (58.3%); 
 
• Limited access to treatment (54.1%). 
 
Additional factors suggested by the experts included: previous history of non-adherence, 
sustance abuse or caregiver/patient personal beliefs of healthcare providers. Details are 
reported in table 2. 
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Table 2 - Challenges in addressing the non-treatment of schizophrenia - PATIENT/CAREGIVER 
FACTORS 
 
 
16.7
4.2
37.5
12.5
29.2
29.2
12.5
8.3
33.3
29.2
20.8
4.2
8.3
12.5
12.5
25.0
25.0
4.2
12.5
20.8
33.3
45.8
79.2
45.8
45.8
50.0
58.3
62.5
29.2
58.3
29.2
8.3
37.5
8.3
12.5
8.3
12.5
8.3
33.4
8.3
41.7
16.7
0% 20% 40% 60% 80% 100%
They do not recognize the problem
Patients suffer from cognitive impairment
Patients suffer from psychotic symptoms
They underestimate the severity of the problem
Limited access to treatment
Lack of awareness of the time course for symptom improvement…
Lack of knowledge about side effects of medications
They are reluctant to see a psychiatrist or other mental health care…
Financial costs to the patients
Stigma and negative perceptions about psychiatric medication and…
Lack of support from family/caregivers to remind patients to take the…
Challenges in addressing the non-treatment of schizophrenia - PATIENT/CAREGIVER 
FACTORS
Strongly Disagree
Disagree
Unsure
Agree
Strongly Agree
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Barriers to change: provider factors 
The majority of the experts stated they strongly agreed/agreed (%) with the following: 
• Lack of training in the interpersonal skills (83.3%); 
 
• Lack of continuity of care with a single clinician (75.0%); 
 
• Poor quality of communication and collaboration between the providers and the 
patients (69.6%); 
 
• Lack of appropriate training or education on schizophrenia (66.7%); 
 
• Lack of appropriate information  on schizophrenia (62.5%); 
 
• The attention is on other phenomena that have become medicalised (52.1%). 
Almost half of the experts reported cultural and ethnic factors (47.8%). 
Additional factors suggested by the experts included: attitude of all staff towards the 
patients; lack of time for motivational interventions, trust building and establishment of a 
therapeutic relationship; under-representation of psychotherapeutic approaches in 
treatment of patients with SMI. Details are reported in table 3. 
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Table 3 – Challenges in addressing the non-treatment of schizophrenia - PROVIDER FACTORS 
 
 
 
20.8
16.7
20.8
4.2
4.3
20.8
33.3
12.5
8.3
8.7
25.0
25.0
8.7
21.7
12.5
25.0
25.0
8.3
21.7
16.7
25.0
8.3
34.8
26.1
45.8
20.8
37.5
50.0
43.5
16.7
25.0
45.8
39.1
34.8
20.8
25.0
33.3
26.1
25.0
4.2
29.2
13.0
13.0
0% 20% 40% 60% 80% 100%
Primary care providers do not receive sufficient
education
Primary care providers may believe that psychiatric
disorders are not "real" illnesses
Primary care providers may also lack sufficient
information on the diagnosis and treatment of…
Primary care providers may have limited training in the
interpersonal skills
Poor quality of communication between the providers
and the patients
Managed care plans can make it difficult for physicians
to prescribe newer medications
Managed care procedures can also inhibit appropriate
referral to a psychiatrist
Lack of continuity of care with a single clinician
The attention is also on other phenomena that have
become medicalised
Cultural and ethnic factors
Challenges in addressing the non-treatment of schizophrenia - PROVIDER 
FACTORS
Strongly
Disagree
Disagree
Unsure
Agree
Strongly
Agree
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Barriers to change: healthcare system factors 
The majority of the experts stated they strongly agreed/agreed (%) with the following: 
• Poor collaboration among the different types of providers (86.4%); 
 
• Difficulties in providing the appropriate service (62.5%); 
 
• The system discourages the proper monitoring of patients once the treatment 
regimen is started (58.3%). 
Only 29.6% strongly agreed/agreed the lack of adequate insurance reimbursement can be 
an issue. 
Additional factors suggested  by the experts included: poor community services, including 
long waiting lists in community centres, lack of non-pharmacological treatments and social 
support, scarce attempt to make a patient feel welcome and valued. Full details are in table 
4. 
 
Expert feedback on the challenges in the evaluation of the impact 
The majority of the experts stated they strongly agreed/agreed (%) with the following 
issues: 
• Choice of sample to include homeless people, prisoners or minors (75%);  
 
• Discrepancies in the information system that supports the management of care or in 
the methods used when assessing patient non-adherence/non-compliance (both 
62.5%).   
Additional factors suggested by the experts included: discrepancy in quality care measures 
(eg self-reported outcome and quality of life); comprehensive evaluation of the patient 
pathway of care from hospital to community; and the role of new long acting injectable 
antipsychotics. Assessment and diagnosis of schizophrenia only by 20.8% strongly 
agreed/agreed. Full details are in table 4. 
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Table 4 - Challenges in addressing the non-treatment of schizophrenia - HEALTHCARE SYSTEM 
FACTORS (panel a) and EVALUATION OF THE IMPACT (panel b) 
 
29.2
4.2
4.2
25.0
16.7
9.1
25.0
16.7
16.7
4.5
16.7
37.5
63.6
37.5
12.5
25.0
22.7
20.8
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Lack of adequate insurance reimbursement
Difficulties in providing the appropriate service
Poor collaboration among the different types of providers
The system discourages the proper monitoring of patients once the
treatment regimen is started
Challenges in addressing the non-treatment of schizophrenia - HEALTHCARE SYSTEM FACTORS (panels a)
Strongly Disagree
Disagree
Unsure
Agree
Strongly Agree
41.7
20.8
4.2
33.3
37.5
16.7
50.0
20.8
45.8
58.3
12.5
16.7
16.7
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Electronic information system
Assessment and diagnosis of schizophrenia
Assessment of non-adherence/ non-compliance
Choice of sample - difficulties in reaching particular groups of the
population in need
Challenges in addressing the non-treatment of schizophrenia - EVALUATION OF THE IMPACT (panel b)
Strongly Disagree
Disagree
Unsure
Agree
Strongly Agree
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Expert feedback on the opportunities in addressing the non-treatment of 
schizophrenia 
The experts were supportive of all the opportunities reported in the literature  (see “what 
can be done” above). They stated they strongly agreed/agreed (%) with the following 
initiatives: 
• Supporting more effective collaboration among providers (100%). 
 
• Ensuring that services are easily accessible by patients (95.8%). 
 
• Promoting the use of tools to remember daily medication doses (91.7%). 
 
• Increasing provider and patient knowledge and understanding about schizophrenia 
or guidelines and protocols accessible to patients and providers (83.3-83.4%). 
 
• Developing performance standards for behavioural health care or enhancing the role 
of patients and their families in decision making (79.2%). 
Additional factors suggested  by the experts included: promoting and implementing 
community care; decreasing waiting times and ensuring that the services are welcoming. 
Full details are in table 5.
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Table 5 – Opportunities in addressing the non-treatment of schizophrenia 
4.2 8.3
4.2
4.2
8.3
4.2
16.7
16.7
8.3
8.3
4.2
50.0
41.7
37.5
54.2
45.8
50.0
66.7
41.7
33.3
41.7
25.0
37.5
50.0
25.0
54.2
0% 20% 40% 60% 80% 100%
Increasing provider knowledge and understanding about…
Increasing patient knowledge and understanding about…
Enhancing the role of patients and their families in decision making
Developing performance standards for behavioral health care
Guidelines and protocols accessible to patients and providers
Supporting more effective collaboration among providers
Promoting the use of tools to remember daily medication doses
Ensuring that services are easily accessible by patients
Opportunities in addressing the non-treatment of schizophrenia
Strongly Disagree
Disagree
Unsure
Agree
Strongly Agree
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Addressing the non-treatment of schizophrenia is an important goal to be met with 
numerous challenges. The care of people with schizophrenia can be vastly improved 
through changes in health service organization and better use of integrated psychological, 
medical, and social interventions. This approach, combined with active engagement on the 
part of people with schizophrenia, their families, and their communities, could lead to 
better lives for all those affected. 
Public health initiatives that may respond better to the growing urgency of the problem 
should target the following aspects:  
• Measuring unmet needs to better understand the scale of the problem, and what 
works in tackling it - Key barriers to be overcome may include the limited access to 
information on particular groups of individuals in great needs (e.g. prisoners, 
homeless people, minors); discrepancies in the information system that supports the 
management of care and in methods used when assessing non-adherence/ non-
compliance or patient self-reported outcomes. 
 
• Engagement on the part of people with schizophrenia, their families, and their 
communities - Increasing patient knowledge and understanding about schizophrenia 
and enhancing the role of patients and their families in decision making. 
 
• Better use of integrated psychological, medical, and social interventions - 
Supporting more effective collaboration among providers; increasing provider 
knowledge and understanding about schizophrenia or guidelines and protocols 
accessible to patients and providers; overcoming current lack of non-
pharmacological treatment and social interventions. 
 
• Changes in health service organization - Ensuring that services are easily accessible 
by patients; promoting the use of tools to remember daily medication doses; 
increasing access to evidence-based services; developing performance standards for 
behavioural health care; promoting and implementing community care; decreasing 
waiting times and ensuring that the services are welcoming. 
Successful initiatives able to improve the outcome of schizophrenia treatment comprise:  
• Expanding the role of the primary care sector with appropriate training and system-
wide support; promoting interdisciplinary collaboration among the different types of 
KEY MESSAGES FOR POLICY AND 
PRACTICE 
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providers; promoting integrated care across settings; and empowering the 
patient/caregiver with effective information, education and participating into the 
decision making process. Awareness campaigns aimed at the general public can be 
beneficial in increasing awareness of the nature of schizophrenia and its treatment.  
 
Key barriers to be overcome would include patients/caregivers (e.g. stigma and negative 
perceptions about psychiatric care and schizophrenia), providers (e.g. primary care 
providers lack of training in the interpersonal skills or education on schizophrenia), 
healthcare system factors (e.g. poor collaboration among the different types of providers 
and settings, difficulties in providing the appropriate service) and researchers (e.g. accessing 
subgroups in greater needs, discrepancies in the assessment of non-adherence).  
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According to the quality of the evidence gathered in both parts 2 (literature review) and 3 
(survey with experts), three different case studies were extrapolated to present evidence on 
the impact of untreated psychosis across different country settings. They include: the 
United States, Germany and Spain. 
National health plans, universal coverage, and 
funding mechanisms 
 
The three case studies present different models of health systems: 
• USA - the health care system is based on the private insurance model.  This model is 
characterised by employment-based or individual purchase of private health 
insurance financed by individual and employer contributions. Service delivery and 
financing are owned and managed by the private entities operating in an open 
market economy. 
 
• Germany - The German health care system is based on the social insurance or 
Bismarck model. Statutory sickness funds and private insurance cover the entire 
population. Payment from employers and employees finance these sickness funds 
and participation is compulsory. Private insurance exists for self-employed 
individuals. The provider network consists of independent private entities. 
 
• Spain - With the introduction of the NHS, financing of health services in Spain shifted 
from the Bismarck model towards the Beveridge model. To date, 80% of funding is 
provided by the state through the generation of taxes, 18% is funded throughout 
work-related contributions to insurance funds shared between the employer and the 
employee and the remainder is financed by other insurance schemes. Co-payments 
apply to drugs and some medical devices (6.1% of all health care expenditure). 
They are summarised in table 6. For more details please refer to the literature (European 
Parliament, 1998) (Kulesher & Elizabeth Forrestal, 2014). 
  
PART 4 – CASE STUDIES 
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Table 6: Case studies: comparing health care systems 
 
Evidence from the literature 
 
Evidence available revolves around the impact of untreated (i.e. lack of treatment for the 
USA only) and non-adherence/compliance to treatment in schizophrenia (and other SMI; 
see table 7). Evidence from the USA publications included:  use of health care and criminal 
justice resources, employment, education, violence and homelessness. Findings for 
Germany and Spain were limited to healthcare resources, employment and violence.  
 
 
 USA Germany Spain 
Universal 
coverage 
No Yes Yes 
National Health 
Insurance 
No No Yes  
Social Insurance No Yes -  No 
Private 
Insurance 
Yes Yes No 
Methods of 
Financing Health 
Care 
Predominant system 
of finance: Private 
Insurance 
Main supplementary 
system of finance:  
Public System 
Financing: Medicare: 
payroll tax, premiums, 
federal tax revenue; 
Medicaid: federal, 
state tax revenue. 
Predominant system of 
finance: public: 
compulsory social 
insurance. Multi-payer 
system in which health 
care is funded by 
private and public 
contributions 
Main supplementary 
system of finance: 
private voluntary 
insurance, direct 
payments, public 
taxation. 
Predominant 
system of finance: 
public: taxation 
Main 
supplementary 
system of finance: 
private voluntary 
insurance, direct 
payments. 
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Table 7: Case studies: evidence on the impact of unmet needs  
 USA (11 papers) Germany (3 papers) Spain (3 papers) 
Use of health resources (hospitalisation, 
emergency services, medications, visits 
with specialists, long-term care/nursing 
homes) 
Impact of untreated psychosis ,  
non-adherence / non –compliance to  
psychotic treatment 
Impact of   non-
adherence / non-
compliance to  
psychotic treatment 
Impact of non-adherence 
/ non-compliance to  
psychotic treatment 
Use of criminal justice resources 
(incarceration) 
Impact of untreated psychosis,  non-
adherence / non –compliance to  
psychotic treatment 
- - 
Employment (unemployment rates, work 
loss) 
Impact of untreated psychosis ,  non-
adherence / non –compliance to  
psychotic treatment 
 
Impact of non-
adherence / non-
compliance to  
psychotic treatment 
Impact of non-adherence 
/ non-compliance to  
psychotic treatment 
Education (level of education achieved, or 
withdrawal from education) 
Impact of untreated psychosis  -  - 
Violence (self-harm or aggressive 
behaviour towards others) and Death 
(suicides, homicides) 
Impact of untreated psychosis,   non-
adherence / non-compliance to  
psychotic treatment 
 
Impact of  non-
adherence / non-
compliance to  
psychotic treatment 
Impact of non-adherence 
/ non-compliance to  
psychotic treatment 
 
Homelessness (use of healthcare 
resources (e.g. hospitalisation, emergency 
services) and housing costs 
Impact of untreated psychosis,    non-
adherence / non –compliance to  
psychotic treatment 
- - 
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Key findings on the impact of untreated 
psychosis 
 
Key findings on the impact of untreated psychosis are limited to the USA case study (see 
table 8). An economic model was developed by The HSM Group, Ltd. to quantify the costs of 
untreated SMI (major depression, bipolar disorder, schizophrenia, anxiety disorders) among 
adults in Greater Kansas City (HSM Group, 2012).  
The prevalence of SMI and percentage of untreated cases - Census data (U.S. Census 
Bureau, 2010) was combined with mental illness prevalence rates (see details presented 
elsewhere: http://hcfgkc.org/costs-untreated-mental-illness) to estimate about 94,500 
cases of untreated SMI in Greater Kansas City. Either individually or in combination, serious 
mental illnesses were reported to affect between 10% and 15% of the population annually 
(schizophrenia accounted for 0.5%). The percentage of untreated cases was near 40% for 
each SMI category (schizophrenia 35.7%). 
The annual costs (Figure 4) - The costs associated with SMI were estimated using peer-
reviewed publications and public datasets. Overall, the annual cost of untreated SMI to 
Greater Kansas City was estimated to be US$624 million (about $6609 per case of untreated 
case of SMI). A high proportion (88%) of these costs was in the form of indirect costs to 
employers and individuals (about US$5785 per case of untreated case of SMI). Indirect costs 
included unrealised earnings due to higher unemployment rates, the cost of lost productive 
time at work due to untreated SMI (presenteeism), time missed from work (absenteeism), 
and unrealised earnings due to permanent disability or premature death (suicides).  
About 10% of the overall costs are estimated to be direct costs, or medical expenses 
associated with lack of sustained treatment (about US$696 per case of untreated case of 
SMI). Direct costs include increased inpatient care/hospitalisations, outpatient care, mental 
health organisation, and long-term care/nursing homes. The remaining costs (2%; $128 per 
case of untreated case of SMI) are due to criminal activity, social security disability, and 
social welfare administration costs. Untreated SMI is associated with an estimated 67 
suicides per year in Greater Kansas City, more than 11,000 incarcerations, and more than 
15,000 unemployed adults. 
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Table 8: The impact of untreated schizophrenia (the evidence is limited to the USA case study) 
Outcomes Evidence 
All outcomes (direct medical costs; indirect costs for 
unemployment, absenteeism, presenteeism and 
premature death;  criminal justice system,  social 
security disability,  social welfare administration)  
(HSM Group, 2012) Annual total costs per case of untreated severe mental illness 
(major depression, bipolar disorder, schizophrenia, anxiety disorders) US$6609 
(2010; greater Kansas City Area, USA) For more information see Figure 4. 
Use of health resources (hospitalisation, emergency 
services, medications, visits with specialists, long-
term care/nursing homes) 
(HSM Group, 2012) Annual total costs per case of untreated severe mental illness 
(Inpatient/hospitalisation, mental health organisation,  outpatient care,  nursing 
home/long term care) US$696 (2010; greater Kansas City Area, USA). 
Use of criminal justice resources (incarceration) (HSM Group, 2012)  Annual total costs of criminal justice system per case of 
untreated severe mental illness US$87 (2010; greater Kansas City Area, USA). 
Employment (unemployment rates, work loss) (Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) The workplace bears a 
significant burden of costs of illness due to untreated and under-treated 
problems. (HSM Group, 2012)  Annual total indirect costs (absenteeism, 
presenteeism, unemployment, premature death) per case of untreated severe 
mental illness US$87 (2010; greater Kansas City Area, USA). 
Education Evidence from the USA showed that untreated subjects often have difficulty in 
school and have an increased likelihood of becoming involved with the juvenile 
justice system (Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009). 
Violence (self-harm or aggressive behaviour towards 
others) and death (suicides, homicides) 
 (HSM Group, 2012)  Untreated SMI is associated with an estimated 67 suicides 
per year in Greater Kansas City (2010; greater Kansas City Area, USA). 
  
 (Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) (Friedman, 2006) 
untreated people with severe mental illnesses (schizophrenia, depressive and 
bipolar disorder) are two to three times as likely as people without such illnesses 
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to be  aggressive and tending to commit an assault. 
  
Homelessness (use of healthcare resources (e.g. 
hospitalisation, emergency services) and housing 
costs) 
(Schnapp WB, Burruss JW, Hickey S, Mortesen K, 2009) People with SMI who 
become homeless have difficulty accessing healthcare. The lack of a permanent 
address, complicated eligibility requirements and daily struggles with their lack of 
(adherence to) treatments are barriers to accessing primary care. This ultimately 
leads to use of higher-cost services such as emergency departments and inpatient 
care. (Culhane, Metraux, & Hadley, 2001) have estimated that these costs are in 
excess of US$28,000 per homeless person per year. 
Cost and impact of non-treating severe mental illnesses (SMIs):  
The case study of schizophrenia                                                                      
 
 
67 
 
Figure 4: Annual cost untreated SMI (US$, per case; adapted from 
HSM Group, 2012) 
 
 
Who pays for the costs (Figure 5) - Preventable hospitalisations, outpatient visits, and 
nursing home stays cost state, federal, and private payers millions of dollars. The estimated 
burden to state and local governments in Greater Kansas City is US$59.6 million annually 
(about US$630 per case of untreated SMI). The burden to the federal government is U$58.7 
million annually (about US$621 per case of untreated SMI).  
Employers would also benefit from a more productive workforce and avoid medical and 
disability costs. Absenteeism and presenteeism cost employers US$228.9 million annually 
(about US$2422 per case of untreated SMI).  
Burden to individuals and families (due to unrealised earnings at work) equals to US$275.2 
million annually (about US$2911 per case of untreated SMI).  
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Figure 5: Annual cost per untreated person with SMI (adpated from 
HSM Group, 2012) 
 
 
Adapting the Greater Kansas City model to Europe and beyond (Table 9) – the annual 
average (direct and indirect) costs per case of untreated SMI in Greater Kansas City (HSM 
Group, 2012) were combined with international estimates of the prevalence (WHO, 2004) 
and treatment gap (Kohn et al., 2004) for schizophrenia to calculate indicative figure of the 
burden of untreated schizophrenia in Europe, Americas and worldwide.  
Raw estimates show that the overall number of cases of untreated schizophrenia would be 
around 8.5 million worldwide, with about 3 million cases between Europe and the Americas. 
The overall economic burden would be about 56 billion US$ worldwide (20 billion US$ 
between Europe and the Americas only). As with any population-based measurement of 
prevalence, caution should be exercised in basing broad conclusions on the present findings. 
The rates presented here may be an underestimation of the real impact of unmet needs in 
schizophrenia (Kohn et al., 2004). Further limitations involve the fact that the economic data 
are based on raw figures from one small study in the USA with limited evidence of the 
quality of data source used and they have been further applied to an international setting.  
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Table 9: The burden of untreated schizophrenia on Europe, 
Americas and worldwide 
 World Americas Europe Sources 
Prevalence Schizophrenia (millions) 26.3 3.9 4.4 WHO, 
2004 
Treatment gap (%) 2.2  56.8 17.8 Kohn et 
al., 2004 
Cost of untreated schizophrenia  
(annual costs US$, per case) 
6,609 6,609 6609 HSM 
Group, 
2012 Cost of untreated schizophrenia  
(indirect annual costs US$, per case) 
5,785  5,785 5,785 
Cost of untreated schizophrenia  
(direct medical annual costs US$, per case) 
696 696 696 
Cost of untreated schizophrenia  
(other annual costs US$, per case) 
128 128 128 
Untreated individuals with 
schizophrenia (million) 
8.5 2.2 0.8  
Cost of untreated schizophrenia  
(total annual costs US$, million) 
55,968  14,640  5,176   
Cost of untreated schizophrenia  
(indirect annual costs US$, million) 
48,992  12,815  4,531   
Cost of untreated schizophrenia  
(direct medical annual costs US$, million) 
5,890  1,541  545   
Cost of untreated schizophrenia  
(other annual costs US$, million) 
1,086  284  100   
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Key findings on the impact of non-
adherence/compliance to treatment 
  
A few studies across the USA, Spain and Germany consistently showed that non-adherence 
is significantly associated with poorer outcomes, including use of health resources (i.e. 
greater risk of hospitalization, greater use of emergency services, longer length of hospital 
stay and greater mean costs) , violence, and greater risk of suicide (see table 10).  
 
Evidence on the use of criminal justice resources, homelessness and unemployment is less 
conclusive and inconsistent across settings. Findings from one of the few studies 
commenting on the association between antipsychotic non-adherence and multiple 
outcome measures are summarised below (see Figure 6). 
 
Figure 6: Association between antipsychotic non- adherence and 
outcomes in a 3-year prospective observational USA study 
(adapted from (H Ascher-Svanum et al., 2006) (Haddad et al. 2014)). 
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Table 10: Case studies: Key findings on the impact of non-adherence to treatment  
 USA Germany  and Spain 
Use of health resources (hospitalisation, 
emergency services, medications, visits 
with specialists, long-term care/nursing 
homes) 
Compared with adherent patients, those who 
were not adherent during the first year were 
more likely to be hospitalised in the following 2 
years (OR 1.55; 95% CI 1.21–1.98) and more 
likely to use emergency psychiatric services in 
the following 2 years (OR 1.49; 95% CI 1.12–
1.98) (Ascher-Svanum et al., 2006) see figure 6. 
The risk of hospitalisation is correlated with the 
degree of non-adherence, with a gap of 1–10 
days in antipsychotic medication being 
associated with an odds ratio for admission of 
1.98, a gap of 11–30 days with an odds ratio of 
2.81, and a gap of more than 30 days with an 
odds ratio of 3.96 (Haddad et al. 2014) (Weiden 
et al., 2004).  
The national re-hospitalisation cost in the USA 
attributable to antipsychotic non-adherence 
was estimated at approximately US$1,500 
million per year in 2005 (Sun et al, 2007). 
Non-adherence is associated with a range 
of poorer long-term outcomes, with 
clinical and economic implications. 
For example: Non-adherence was 
significantly associated with an increased 
risk of relapse (OR 0.58; 95% CI 0.49–0.69), 
hospitalisation (OR 0.61; 95% CI 0.53–
0.70) and suicide attempts (OR 0.60; 0.43–
0.85) (Novick et al., 2010). 
Annual costs incurred by EU patients 
(Germany, Italy, Spain, France, Denmark, 
Greece, Ireland/the UK, the Netherlands, 
Portugal) who ever relapsed (as 
consequence of their non-adherence; 
£14,055 total cost per patient in 2005) 
during three years were almost double to 
those incurred by patients who never 
relapsed (£7417). 61% of the cost 
difference was accounted for by hospital 
stay. The impact of relapse was even 
greater in the 1-year cost (Hong et al., 
2009).   
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Use of criminal justice resources 
(incarceration) 
(H Ascher-Svanum et al., 2006) Non-adherence 
was associated with poorer functional 
outcomes, including greater risks of arrests   
compared with adherent patients (8.4% versus 
3.5%; p < 0.001) (Figure 6).  
 
- 
Employment (unemployment rates, work 
loss) 
- Relapsers had an earlier onset of 
schizophrenia and had a poorer level of 
social functioning at baseline (i.e. a lower 
frequency of paid employment and social 
contacts in previous 4 weeks; (Hong et al., 
2009)). 
Violence (self-harm or aggressive 
behaviour towards others) and death 
(suicides, homicides) 
Non-adherence is associated with a 
significantly higher rate of violence, 
victimisation, and substance use (Figure 6) (H 
Ascher-Svanum et al., 2006) (Haddad et al., 
2014). 
(Higashi et al., 2013) reported that non-
adherence to schizophrenia medication 
increases the risk of suicide fourfold (relative 
risk adjusted for age and gender 4.2, 95% CI 
1.7– 10.1) while another review (Llorca, 2008) 
reported that non-adherent patients 
(documented refusal of oral or depot injection) 
were at seven times greater risk of suicide. In a 
large prospective multisite study which included 
1906 patients, non-adherent patients were 
more than twice as likely to be violent than 
adherent patients (10.8% versus 4.8%; p < 
Non-adherence was significantly 
associated with an increased risk of 
suicide attempts (OR 0.60; 0.43–0.85) 
(Novick et al., 2010). 
More relapsers (5.8%) had suicide 
attempts in the six months before 
baseline, compared to non-relapsers 
(3.3%; p<0.01; Hong et al., 2009). 
Spain only: Arango 2006 - Treatment non-
adherence is predictor of violence.  
Violent patients presented fewer months 
of adherence to medication and a lower 
rate of adherence during follow-up 
compared with non-violent patients 
(P<0.01). 
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0.001).   
Homelessness (use of healthcare 
resources (e.g. hospitalisation, emergency 
services) and housing costs) 
(Schnapp WB, Burruss JW, Hickey S, Mortesen K, 
2009) People with SMI who become homeless 
have difficulty accessing healthcare. The lack of 
a permanent address, complicated eligibility 
requirements and daily struggles with their lack 
of (adherence to) treatments are barriers to 
accessing primary care. This ultimately leads to 
use of higher-cost services such as emergency 
departments and inpatient care.  (Culhane et 
al., 2001) have estimated that these costs are 
in excess of US$28,000 per homeless person 
per year. 
- 
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Challenges and future opportunities 
 
The expert survey data (see part 3) were reanalysed to compare evidence gathered from 
experts based in the USA (4), Germany (5) and Spain (3). Please note that the small sample 
size did not allow testing the significance of the difference between groups. 
Challenges in addressing the non-treatment of schizophrenia - 
PATIENT/CAREGIVER FACTORS  
The majority of the experts stated they strongly agreed/agreed (%) with the following: 
 
More details are in table 11. 
 
USA
• Stigma and negative 
perceptions about 
schizophrenia (100%)
• Lack of knowledge 
about side effects of 
medications (100%)
• Financial costs to the 
patients (100%)
• Lack of illness 
awareness (75%)
• Lack of severity 
awareness (75%)
• Lack of awareness of 
the time course for 
symptom 
improvement (75%)
• The direct impact of 
symptoms (75%)
• Limited access to 
treatment (75%)
• Lack of support from 
family/caregivers 
(75%)
Germany
• Stigma and negative 
perceptions about 
schizophrenia (100%)
• The direct impact of 
symptoms (100%)
• Lack of severity 
awareness (60%)
• Lack of awareness of 
the time course for 
symptom 
improvement (60%)
• Limited access to 
treatment (60%)
• Lack of support from 
family/caregivers 
(60%)
Spain
• Stigma and negative 
perceptions about 
schizophrenia (100%)
• The direct impact of 
symptoms (100%)
• Lack of illness 
awareness (67%)
• Lack of severity 
awareness (67%)
• Lack of knowledge 
about side effects of 
medications (67%)
• Limited access to 
treatment (67%)
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Table 11 – Case studies: Challenges in addressing the non-treatment of schizophrenia - 
PATIENT/CAREGIVER FACTORS (agreed/strongly agreed %) 
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Challenges in addressing the non-treatment of schizophrenia -  
PROVIDER FACTORS 
The majority of the experts stated they strongly agreed/agreed (%)with the following: 
 
More details are in table 12. 
USA
• Lack of training and 
education on 
schizophrenia (100%)
• Lack of training in the 
interpersonal skills 
(100%)
• Poor quality of 
communication 
between the 
providers and the 
patients (100%)
• Lack of continuity of 
care (100%)
• Lack of appropriate 
information on 
diagnosis and 
treatment (75%)
• Care plan limitations 
(75%)
• Cultural and ethnic 
factors (67%)
• The attention is also 
on other phenomena 
that have become 
medicalised (50%) 
Germany
• Lack of training in the 
interpersonal skills 
(80%)
• Lack of appropriate 
information on 
diagnosis and 
treatment (80%)
• Lack of training and 
education on 
schizophrenia (60%)
• Poor quality of 
communication 
between the providers 
and the patients (60%)
• Cultural and ethnic 
factors (60%)
Spain
• Lack of training in the 
interpersonal skills 
(100%)
• Cultural and ethnic 
factors (100%)
• Poor quality of 
communication 
between the providers 
and the patients (67%)
• Care plan limitations 
(67%)
• Lack of continuity of 
care (67%)
• The attention is also 
on other phenomena 
that have become 
medicalised (67%)
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Table 12 – Case studies: Challenges in addressing the non-treatment of schizophrenia - PROVIDER 
FACTORS (agreed/strongly agreed %) 
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Challenges in addressing the non-treatment of schizophrenia -  
HEALTHCARE SYSTEM FACTORS 
The majority of the experts stated they strongly agreed/agreed (%)with the following: 
 
More details are in table 13. 
USA
• Lack of adequate 
insurance 
reimbursement 
(100%)
• Difficulties in 
providing the 
appropriate service 
(100%)
• Poor collaboration 
among the different 
types of providers 
(100%)
• The system 
discourages the 
proper monitoring of 
patients (50%)
Germany
• Poor collaboration 
among the different 
types of providers 
(80%)
• The system 
discourages the 
proper monitoring of 
patients (60%)
Spain
• Poor collaboration 
among the different 
types of providers 
(100%)
• Difficulties in 
providing the 
appropriate service 
(67%)
• The system 
discourages the 
proper monitoring of 
patients (67%)
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Table 13 – Case studies: Challenges in addressing the non-treatment of schizophrenia - HEALTHCARE 
SYSTEM FACTORS (agreed/strongly agreed %) 
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Challenges in addressing the non-treatment of schizophrenia -  
EVALUATION OF THE IMPACT 
The majority of the experts stated they strongly agreed/agreed (%)with the following: 
 
More details are in table 14. 
USA
• Choice of sample 
(100%)
• Discrepancies in the 
information system 
that supports the 
managment of care 
(75%)
• Discrepancies 
between the different 
criteria used for the 
assessment of non-
adherence/ non-
compliance (75%)
Germany
• Choice of sample 
(80%)
• Discrepancies in the 
information system 
that supports the 
management of care 
(60%)
• Discrepancies 
between the different 
criteria used for the 
assessment of non-
adherence/ non-
compliance (60%)
Spain
• Discrepancies in the 
information system 
that supports the 
management of care 
(100%)
• Discrepancies 
between the different 
criteria used for the 
assessment of non-
adherence/ non-
compliance (100%)
• Choice of sample 
(100%)
• Discrepancies 
between the different 
criteria used for the 
diagnosis (67%)
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Table 14- Case studies: Challenges in addressing the non-treatment of schizophrenia - EVALUATION OF 
THE IMPACT (agreed/strongly agreed %) 
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Opportunities in addressing the non-treatment of schizophrenia 
The majority of the experts stated they strongly agreed/agreed (%)with the following: 
 
More details are in table 15. 
USA
• Supporting more 
effective 
collaboration among 
providers (100%)
• Ensuring that services 
are easily accessible 
by patients (100%)
• Increasing provider 
knowledge and 
understanding about 
schizophrenia (100%)
• Enhancing the role of 
patients and their 
families in decision 
making (100%)
• Providing care 
treatment guidelines 
and protocols 
accessible to patients 
and providers (100%)
• Promoting the use of 
tools to remember 
daily medication 
doses (100%)
• Increasing patient 
knowledge and 
understanding about 
schizophrenia (75%)
• Developing 
performance 
standards for 
behavioural health 
care (50%)
Germany
• Supporting more 
effective 
collaboration among 
providers (100%)
• Ensuring that services 
are easily accessible 
by patients (100%)
• Increasing patient 
knowledge and 
understanding about 
schizophrenia (80%)
• Increasing provider 
knowledge and 
understanding about 
schizophrenia (80%)
• Enhancing the role of 
patients and their 
families in decision 
making (80%)
• Providing care 
treatment guidelines 
and protocols 
accessible to patients 
and providers (80%)
• Promoting the use of 
tools to remember 
daily medication 
doses (80%)
• Developing 
performance 
standards for 
behavioural health 
care (80%)
Spain
• Supporting more 
effective 
collaboration among 
providers (100%)
• Ensuring that services 
are easily accessible 
by patients (100%)
• Increasing patient 
knowledge and 
understanding about 
schizophrenia (100%)
• Developing 
performance 
standards for 
behavioural health 
care (100%)
• Increasing provider 
knowledge and 
understanding about 
schizophrenia (67%)
• Providing care 
treatment guidelines 
and protocols 
accessible to patients 
and providers (67%)
• Promoting the use of 
tools to remember 
daily medication 
doses (67%)
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Table 15 – Case studies: Opportunities in addressing the non-treatment of schizophrenia (agreed/strongly 
agreed %) 
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Discrepancy of evidence across settings: the 
USA present stronger evidence than others 
 
Access to data on the diagnosis, care and treatment gap of schizophrenia may vary 
according to country setting.  
The economic evidence available is very limited (mainly on the USA); however it shows a 
massive impact of unmet needs on healthcare and society overall: 
• In the USA (Greater Kansas City) the annual cost of lack of treatment for severe 
mental illness is  about $6609 per case, 2010 figures (HSM Group, 2012). A high 
proportion (88%) of these costs is in the form of indirect costs to employers and 
individuals (about U$5785 per case of untreated SMI). About 10 % of the overall 
costs are estimated to be direct costs, or medical expenses associated with lack of 
sustained treatment (about US$696 per case of untreated SMI).  
 
When adapting the Greater Kansas City model to international estimates of the 
prevalence and treatment gap for schizophrenia the overall number of cases of 
untreated schizophrenia would be around 8.5 million worldwide, with about 3 
million cases between Europe and the Americas. The overall economic burden would 
be about 56 billion US$ worldwide. 
 
• In the USA the national re-hospitalisation cost attributable to antipsychotic non-
adherence is estimated at approximately US$1,500 million per year (2005 figures). 
Data available from the literature review could be used to model unmet needs across 
multiple scenarios and settings where there is lack of quality evidence. 
 
Common challenges and opportunities in the 
three case studies: the expert views 
 
Patient factors - Due to stigma and a lack of awareness and understanding of mental illness, 
a substantial proportion of mental disorders in OECD countries is undiagnosed, untreated or 
undertreated (OECD, 2014). 
KEY MESSAGES 
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• Stigma and negative perception about schizophrenia are top priories in all countries. 
People suffering from mental health have to cope not only with symptoms 
associated with mental disorders, but also with stigma and prejudice – a “second 
illness” that frequently inhibits recovery from the first. Not only mental health-
related stigma results in social isolation, low self-esteem, and more limited chances 
in areas such as employment, education and housing, but it also exacerbates unmet 
needs, reducing early interventions and increasing the treatment gap for mental 
illness (OECD, 2014). OECD countries have used legislation to protect the rights of 
people with mental disorders both in the community and in inpatient settings, 
although people with mental disorders still face discrimination, stigma, and 
marginalisation from society, which in turn increases the risk of violation of their 
rights (OECD, 2014). 
 
• In all case studies it also recognised that symptoms of schizophrenia itself (such as 
depression, cognitive impairment, positive and negative symptoms) can reduce 
awareness of physical problems, reduce capacity to take action to seek help and use 
health care services, leading to untreated or poorly managed schizophrenia. 
 
• Person-centred care, a model of care that takes into account patient’s preferences 
and needs, ensures continuity of care, develops partnerships with caregivers and 
patients, and treats the patient as a person and not only the symptoms, is commonly 
recognised as a crucial element to overcome the challenge of unmet needs in 
schizophrenia (OECD, 2014). 
 
Provider and health system factors - All the experts from the three countries reported that 
communication and collaboration across healthcare providers, training, patient and 
stakeholder involvement, and use of mechanisms for measurement of quality care are all 
essential to successful implementation of new and changing work practices to address 
unmet needs (OECD, 2014).  
• Lack of communication and interpersonal skills. It is commonly recognised that there 
is a lack of alliance between the providers and the patients/their families to ensure 
that recommendations on treatment goals and strategies are met.  
 
• Clear communication and co-ordination between primary care, specialist mental 
health care and the patient are vital to promote adequate coordination of mental 
health services, follow-up and care management once the physical health problem 
has been identified. Co-ordination of mental health services is crucial in order to 
guarantee the continuity of care for people with mental disorders who are often lost 
to follow up (OECD, 2014).  Professional experts across country case studies 
recognise that when the system discourages such cooperation between parties in 
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the monitoring of patient there is an increased risk of under treatment or non-
adherence to treatment. 
 
• The majority of the experts recognised that health care providers do believe that 
psychiatric disorders are real illnesses, regardless of their country of residence. 
 
• In all case studies it is recognised that discrepancies in electronic information 
system, in the assessment of non-adherence/non-compliance and in reaching 
particular groups of the population in needs are common challenges in the 
evaluation of the unmet needs.  
 
Discrepancies in challenges and opportunities across the three case 
studies:  the expert views 
 
Different experience of healthcare systems, health service delivery and culture may 
influence possible challenges and opportunities to tackle unmet needs. 
Patient factors  
• Lack of support from family and caregivers. Experts from USA and Germany may 
confirm that there is a lack of support from family and caregivers in the management 
of the medication as possible cause of poor adherence (Fleischhacker et al., 2014).  
This is not so evident in different cultural contexts (see Spain) where the family plays 
a stronger role in supporting its members when they are in need of care.  
 
• Financial costs to the patients. In the USA, where the health care system is based on 
the private insurance model, financial costs are considered strong challenges for the 
patients, whereas in other countries (based on national health insurance – Spain - 
and social health insurance – Germany) this factor is of less relevance. 
 
• Other discrepancies in findings across case studies include lack of awareness of the 
problem, or the course of the symptoms as well as poor knowledge of the side 
effects.  
Provider and health system factors 
• Primary care providers do not receive sufficient education and information. In the 
USA it is recognised that few medical schools do not provide sufficient education 
about psychiatric diagnosis, psychopharmacology, or psychotherapy for depression 
(Hirschfeld et al., 1997). Postgraduate education of primary care providers may also 
lack sufficient information on the diagnosis and treatment of psychosis. The 
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physician may be inadequately prepared to use the most modern methods. In 
addition, many providers have limited training in the interpersonal skills that enable 
them to manage emotional distress. This may lead to their avoidance of addressing 
schizophrenia and other mood disorders (Hirschfeld et al., 1997). In other countries, 
such Germany or Spain this lack of training and education may not be so evident. 
OECD data on the frequency of new graduate mental health professionals per 
100,000 in population (OECD, 2014) confirmed discrepancies between the USA and 
other countries. For example Germany presented a higher level of newly educated 
professionals who can attend more advanced postgraduate degree courses in 
“psychiatry and psychotherapy” compared with the USA. In Germany the 
professional group of psychiatrists has had a relatively constant net increase of 4.5% 
over the last few years making it the fastest growing medical speciality. A similar 
development is observed for psychological psychotherapists (OECD, 2014). 
 
• Lack of adequate insurance reimbursement. In the USA (where the predominant 
system of finance is private insurance) many insurance and managed care companies 
actively discourage patients from seeing mental health care professionals. 
Furthermore, when care for psychosis is rendered directly by a primary care 
physician, there may still be difficulties in obtaining reimbursement (Hirschfeld et al., 
1997). Such issues are not currently present in other countries (e.g. Germany or 
Spain) with different methods of financing care. 
 
• Management of care procedure can also inhibit appropriate referral in place. In the 
USA, the difficulties in providing the appropriate service are more evident than in 
other countries and this may be due to a more evident lack of collaboration between 
healthcare providers (Hirschfeld et al., 1997). For example, physicians may restrict 
their approach to medication and fail to refer patients to other providers for 
psychotherapy when it might be useful in addition to antipsychotic drugs. 
Psychotherapists may similarly fail to refer patients to a physician for evaluation of 
the possible benefits from taking medication. Cost-saving plans in the managed care 
system often discourage providers from "sharing" patients or providing 
psychotherapy (Hirschfeld et al., 1997).  
 
• Performance indicators. Mental health care outcomes are too rarely measured and 
monitored, often due to a lack of good outcomes indicators, or a framework 
establishing desirable and undesirable outcomes. Developing performance standard 
for behavioural healthcare constitutes a clear opportunity to tackle unmet needs 
across countries. A lack of agreement over which key measures can capture good 
treatment outcomes for mental health has limited any progress in driving towards 
better outcomes. However, despite the challenge of coming up with such a 
framework, countries such as the USA, do have already in place a system to measure 
outcomes in mental health (OECD, 2014) and may value more other initiatives 
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compared with developing performance standards (see responses from experts: 
Spain 100%, Germany 80%, USA 50%). 
 
• Other discrepancies include difference in cultural and ethical factors and in 
management of care plan that may limit the prescription of new medications (e.g. 
USA) more than in other countries (e.g. Germany). Countries such as Spain, where 
patients and stakeholders are less experienced about patients centred-decision 
making, may value less enhancing the role of patients and their families in decision 
making compared with other countries (such as USA and Germany where such 
practices has been in use in healthcare for longer time and there is already evidence  
of their benefit) (Perestelo-Perez, Gonzalez-Lorenzo, Perez-Ramos, Rivero-Santana, 
& Serrano-Aguilar, 2011). 
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Appendix 1 - Mesh terms and search strategy 
 Operator # MeSH term 
(explode all trees) 
Operator # Corresponding text words 
Population: Severe 
mental illness 
 
 
( 1 [mh "Mental 
disorder”] 
( 25  “severe mental illness” OR “severe mental illnesses” OR 
“severe mental disorders” OR Psychosis OR “severe mental 
disorder” OR “major mental illnesses” OR “major mental 
disorders” OR “major mental illness” OR “major mental 
disorder”  
Population: 
Schizophrenia 
 
OR) 2 [mh 
"Schizophrenia”] 
 
OR) 26 “Schizophrenia” OR “Schizophrenic Disorders”  OR 
“Schizophrenic Disorder”   
 
Outcome: 
Cost/burden/unmet 
needs/impact on health 
and social care 
resources 
AND ( 3 [mh "Costs and Cost 
Analysis"] OR  
[mh Health Care 
Costs] 
AND ( 27 Costs or cost OR Costing OR Expenditure OR (Financial (cost 
OR benefit OR burden)) OR Saving OR Economic OR “Health 
Care Costs” OR 
“Service use” OR “resource use” OR “Service utilisation” OR 
“resource utilisation” OR “Service utilization” OR “resource 
utilization” OR “Service contact” OR “resource contact” OR 
“economic consequences” OR “social and economic 
consequences” 
OR 4 [mh "Cost of 
Illness”] 
OR 28 “Cost of illness” OR “burden of illness” OR “Cost of Disease” 
OR “Cost of Sickness” OR “Costs of Disease” OR “Disease 
Cost?” OR “Sickness Cost” 
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OR 5 [mh “Cost-Benefit 
Analysis”] 
 
OR 29 Cost-Benefit OR “Cost Benefit” OR 
“Costs and Benefits” OR 
“Benefits and Costs” OR 
 “Cost-Benefit Analyses” OR 
“Cost Benefit Analysis” OR 
“Cost Effectiveness” OR 
 “Cost-Benefit Data” OR 
“Cost Benefit Data” 
OR 6 [mh "Health 
Services Misuse”] 
OR 30 “Health Service Misuse” OR “Health Service underuse” OR 
“Health Services Misuse” OR “Health Services underuse” OR 
“misuse of services” OR “misuse of health services” OR 
“misuse of healthcare services” 
OR 7 [mh"Social 
Work/utilization"] 
[mh "Social Work, 
Psychiatric/utilizatio
n"] [mh "Social 
Welfare/utilization"] 
OR 31 “Social care misuse” OR “social care underuse” 
OR 8 [mh "Social Change] OR 32 “Social impact” OR  “social change” 
Outcome: Intangible 
costs 
     “Intangible costs” OR “Intangible cost” OR Disability 
adjusted life years lost” OR DALY OR “morbidity outcomes”  
Outcome: Criminal 
justice resources 
 
OR 9 [mh Criminal Law], 
[mh prison] 
 
OR 33 “Criminal justice” OR prison OR crime 
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Outcome: Violence and 
death (suicides, 
homicides) 
OR 10 [mh Violence], [mh 
death], [mh Suicide], 
[mh homicide] 
OR 34 Violence OR death OR “premature death” OR Suicide, 
homicide, killing OR Murder OR killings OR Murders Or 
“self-harm” OR “premature mortality”  
Outcome: Education OR 11 [mh “Educational 
Status”], [mh 
education] 
OR 35 “Educational Status” OR education OR schooling 
Outcome: Employment OR 12 [mh Career], [mh 
employment], [mh 
Absenteeism] 
OR 36 Career OR employment OR Absenteeism OR productivity 
OR “missed work” OR “sickness absence” OR presenteeism 
OR unemployment OR underemployment OR “disability 
claims” OR “benefit claims” OR “disability claim” OR 
“benefit claim” OR “value of lost production” 
Outcome: 
Homelessness 
OR 13 [mh “Homeless 
Persons”] 
 
OR 37 “Homeless Person” OR “Homeless Persons” OR Homeless 
OR Homelessness OR “Street People” 
Outcome: 
Comorbidities 
OR) 14 [mh “Comorbidity”] 
 
OR) 38 Comorbidity OR comorbidities  
Comparison: Missed 
diagnosis 
AND ( 15 [mh "Delayed 
Diagnosis"] 
AND ( 39 “Missed diagnosis” OR “misdiagnosis” OR “under-
diagnosed” OR “underrecognised” OR unrecognised OR 
under recorded OR “Unmet Needs in Diagnosis” OR 
"Delayed Diagnosis" OR “lack of diagnosis” 
Comparison: Missed 
treatment/delayed 
treatment 
OR 16  OR 40 “treatment gap” OR “non-treatment” OR “non-treating” OR 
“under-treated” OR untreated OR “never treated” OR 
“duration of untreated” OR untreated OR “Inaccessible 
treatment” OR 
“Failure in Initial Treatment” OR  “Delay in Initial 
Treatment” OR “delayed treatment” OR “non-seeking 
treatment” OR “Unmet Needs in Treatment” OR “Unmet 
Need in Treatment” OR “inadequately treated” OR “lack of 
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treatment” OR “insufficiently treated” 
Comparison: 
Inappropriate therapy 
OR 17  OR 41 “Non-efficacious therapy” OR “Non-efficacious treatment” 
OR “Non-efficacious care” OR mistreated OR mistreatment 
OR “inappropriate treatment” OR “inappropriate therapy” 
OR “inappropriate care” 
Comparison: Patient 
lack of adherence/ 
compliance 
OR 18 [mh “Patient 
Compliance”] 
OR 42  “lack of compliance” OR “non-compliance” OR “non-
compliant” OR “non-adherence” OR “lack of adherence” OR 
“Patient Non-Adherence” OR  “Patient Non-Compliance” 
OR “Patient Nonadherence” OR “Patient Noncompliance” 
OR “lack of Patient Cooperation” 
Comparison: Patient 
refusal 
OR) 19 [mh “Treatment 
Refusal”] 
OR) 43 “Refusal of Treatment” OR “Patient Refusal of Treatment” 
Geography AND ( 20 [mh “North 
America”] 
AND  44 “North America” OR USA OR “United States” OR UK OR 
“Great Britain” OR “United Kingdom” OR England OR Wales 
OR Scotland OR “Northern Ireland” OR Australia OR 
Oceania OR “New Zealand” OR Austria OR Belgium OR 
Canada OR “Czech Republic” OR Denmark OR Estonia OR 
Finland OR France OR Germany OR Greece OR Hungary OR 
Iceland OR Ireland OR Israel OR Italy OR Luxembourg OR 
Netherlands OR Norway OR Poland  
OR Portugal OR “Slovak Republic” OR Slovenia OR Spain OR 
Sweden OR Switzerland OR Chile OR Japan Or Korea Or 
Mexico OR ((developed OR OECD OR (high NEXT income) 
OR industrialised) NEXT (country OR nation?))  
 
OR 21 [mh “Europe”]  
OR 22 [mh “Australia”]  
OR 23 [mh “Oceania”]  
OR) 24 [mh “Developed 
countries”] 
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Appendix 2- Summary of the evidence according to publications 
Reference Nationality Date Population Study design Comparison Outcomes Results 
(Arango et al., 
2006) 
Spain 2006 Patients treated 
for 
schizophrenia 
RCT Non 
adherence 
 Violence  Violence - In a randomised clinical trial 
comparing different formulations of 
zuclopenthixol in patients with schizophrenia 
and previous violence, violent acts during the 
follow-up year were inversely proportional to 
treatment adherence, better compliance, and 
greater reduction of positive symptoms. 
(Haya Ascher-
Svanum, Zhu, 
Faries, Lacro, 
& Dolder, 
2006) 
 
USA 2006 Patients treated 
for 
schizophrenia 
Prospective, 
observational 
Non 
adherence 
Health Care 
Utilisation, Use 
Of Criminal 
Justice 
Resources, 
Violence 
Utilization health care -antipsychotic non 
adherence was related to an increase in 
hospitalisation rate, hospital days or hospital 
costs. Use of criminal justice resources – Non-
adherence was associated with poorer 
functional outcomes, including greater risks not 
only of psychiatric hospitalisations, use of 
emergency psychiatric services, but also of 
arrests, violence, victimisations, poorer mental 
functioning, poorer life satisfaction, greater 
substance use, and more alcohol-related 
problems (all p < 0.01). Violence - lack of 
adherence was associated with poorer 
outcomes, including increased act of violence. 
(Bodén et al., 
2011) 
Sweden 2011 Patients with 
schizophrenia 
Prospective, 
observational 
Non 
adherence 
Health Care 
Utilisation 
Utilization health care -antipsychotic non- 
adherence was related to an increase in 
hospitalisation rate, hospital days or hospital 
costs. 
(Cechnicki et Poland 2014 Participants 
with 
Prospective, Untreated Health Care 
Utilisation, 
Use of health care resources They found a lack 
of correlation between use of health resources 
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al., 2014) 
 
schizophrenia  observational psychosis Employment (number of re-hospitalisations and duration of 
re-hospitalisations) and duration of untreated 
psychosis DUP. In terms of employment, the 
relationship between longer DUP and worse 
employment outcome was statistically 
significant at 7 and 12 years from first 
hospitalization. 
(Challis, 
Nielssen, 
Harris, & 
Large, 2013) 
 
International 
literature, 
unspecified 
2013 Patients with 
schizophrenia  
 Systematic 
review and 
meta-analysis 
Untreated 
psychosis 
 Violence Violence - DUP was associated with an 
increased risk of deliberate self-harm 
(Damen et al., 
2008) 
 
 
Sweden 2008 Patients with 
schizophrenia 
Discrete 
event 
simulation 
model 
Non-
compliance 
Utilisation 
Healthcare 
Utilization health care The authors compared 
staying on branded risperidone with generic 
substitution; differences between treatments 
included the probability of non-compliance and 
medication costs. The model predicted that it 
was cost-effective to keep a patient with 
schizophrenia in Germany on branded 
risperidone instead of switching them to 
generic risperidone (with a 40% reduction in 
medication costs and an incremental 
probability of becoming non-compliant after 
generic substitution greater than 5.2%). 
(Dilla et al., 
2013) 
USA, UK and 
New Zeeland 
2013 patients with 
schizophrenia 
Systematic 
review 
Non-
adherence to, 
anti-psychotic 
medication 
Utilisation 
Healthcare 
Utilization health care This systematic review 
of the economic aspects of non-adherence to 
antipsychotic medication in patients with 
schizophrenia showed that poor adherence to 
antipsychotic treatment is linked to increased 
hospitalisation rates and resource utilisation 
which resulted in increased direct health care 
costs. 
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(Fazel et al., 
2010) 
 
Sweden 2010 Patients with 
psychosis 
patients with 
schizophrenia 
and other 
psychoses 
Prospective 
case control  
Non- 
compliance 
Death Death - When looking at homicide in 
discharged patients with schizophrenia and 
other psychoses in Sweden, common factors 
associated with homicide were evidence of 
medication non-compliance and substance 
misuse. 
(Foley et al., 
2007) 
 
Ireland 2007 With a diagnosis 
of psychotic 
illness 
Retro-
spective, 
observa-
tional 
Non- 
adherence 
Violence Violence - In contrast with other evidence,  
(Foley et al., 2007)  did not find an association 
between violence at presentation and DUP. 
The relationships between violence, DUP and 
psychopathology may be confounded by 
potential difficulties inherent in the PANSS. 
(Heeg et al., 
2005) 
UK 2005 Patients with 
schizophrenia 
discrete event 
simulation 
(DES) model 
Non- 
compliance 
utilisation 
healthcare 
Use of health care resources -  (Heeg et al., 
2005) developed a model to incorporate social 
and environmental factors into the decision-
making process for the prescription of new 
drugs to patients. The model was used to 
analyse the potential benefits of improving 
compliance with medication by 20% in patients 
in the UK. A 20% increase in compliance was 
estimated to save £16 147 and to avoid 0.55 
psychotic episodes per patient over 5 years. 
Sensitivity analysis showed that the costs 
savings associated with increased compliance 
are robust over a range of variations in 
parameters. 
(Hensen et al., 
2010) 
Sweden 2010 Patients with 
schizophrenia 
discrete event 
simulation 
(DES) model 
Non- 
compliance 
utilisation 
healthcare 
(Hensen et al., 2010) looked at the cost 
effectiveness of long-acting risperidone in 
Sweden and confirmed that compliance is the 
main driver of the cost effectiveness of the 
medicine. 
(Higashi et al., International 2013 Details are Systematic Non- Health Care Use of health care resources - we can identify a 
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2013) literature, 
unspecified 
missing literature 
review 
adherence Utilisation, 
Employment, 
Education, 
Death 
clear link between non adherence and an 
increased risk of hospitalisation , use of 
emergency psychiatric services, longer length 
of hospital stay. Employment, Education - Non-
adherence, partial adherence can create a 
downward spiral of events leading to 
inconsistent symptom control, relapse and 
rehospitalisation, which in turn can lead to 
long-term functional disabilities, loss of 
employment and education possibilities. 
Death – non-adherence to antipsychotic 
medication is one of the risk factors for the 
development of suicidal behaviour in patients 
with schizophrenia. 
(Hill et al., 
2012) 
 
Ireland 2012 Patients with 
psychosis  
Prospective, 
observational 
Non- 
adherence 
 Employment Employment - the authors reported no 
association between DUP and gainful 
employment over 12 years. 
HSM Group. 
(2012) 
USA 2012 Patients with 
schizophrenia 
and other 
psychoses 
Model’s 
estimates 
Untreated 
psychosis 
Use Of Health 
Care 
Resources, Use 
Of Criminal 
Justice 
Resources, 
Employment, 
Death 
Use of health care resources - In Greater 
Kansas City the annual inpatient 
hospitalizations costs for untreated 
schizophrenia was estimated as $39.9 million 
higher compared with patients receiving 
regular care (modelling based on 2011 
estimates). The annual outpatient care costs 
for untreated schizophrenia were $6.7 million 
higher compared with patients receiving 
regular care.  
Use of criminal justice resources - In Greater 
Kansas City, the annual incarceration costs of 
individuals with severe mental illness resulted 
in $8.2 million to the criminal justice system 
(2011 estimates). Employment - overall about 
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24% of individuals with severe mental illness 
are unemployed at any given time, and about 
half of those cases are due to lack of 
treatment. In Greater Kansas City, this can lead 
to more than 15,000 adults who are 
unemployed due to lack of treatment for SMI. 
Death - The model estimated 67 suicides in 
Greater Kansas City can be attributed to SMI 
annually 
(King et al., 
2014) 
the 
Netherlands, 
Germany, UK 
and Italy 
2014 patients with 
schizophrenia 
RCT Non- 
adherence 
Health and 
social care 
utilization 
Utilization health and social care - In a 
multicountry RCT based in UK, Italy, Germany 
and the Netherlands looking at the impact of 
non-adherence to medication in patients with 
schizophrenia  (King et al., 2014) showed that 
the effect of non-adherence was not 
statistically significantly associated with health 
and social care costs, whereas patients who 
reported non-adherence had significantly lower 
societal costs than those reporting adherence. 
(Knapp, King, 
Pugner, & 
Lapuerta, 
2004a) 
 
 
UK 2004 Patients living in 
institutions ions 
that they had 
been prescribed 
anti-psychotic 
medication 
Cross-
sectional  
Non- 
adherence 
Utilization 
Health Care 
Utilization health care -antipsychotic non- 
adherence was related to an increase in 
hospitalisation rate, hospital days or hospital 
costs. 
(Lim et al., 
2008) 
 
 
Canada 2008 Adult 
population aged 
20 and above 
Cross-
sectional  
Undiagnosed 
mental illness 
Health Care 
Utilisation, 
Employment 
The utilisation of all health care services was 
highest for the diagnosed mentally ill, lowest 
for the non-mentally ill, with those in the 
undiagnosed category in the middle. The 
average medical cost per capita was C$643 for 
the non-mentally ill and C$2,515 for the 
diagnosed and C$1,442 for the undiagnosed 
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(2003 figures).  
Employment - The authors reported that 
absenteeism (long-term work loss) is highest 
for the diagnosed mentally ill, lowest for the 
non-mentally ill, with those in the undiagnosed 
category in the middle. Unemployment rate is 
highest for the diagnosed 0.46%, but a smaller 
group of undiagnosed (0.26%) were 
unemployed compared with people with no 
mental illness (0.33%). The number of disability 
days per year (short- term work loss) were, 
respectively:  33 (diagnosed mentally ill), 27 
(undiagnosed mentally ill), and 10 (non-
mentally ill).  
(Llorca, 2008) International 
literature, 
unspecified 
2008 Patients with 
schizophrenia 
Systematic 
literature 
review 
Non- 
compliance 
Utilisation 
Healthcare, 
Employment,  
Violence/Death
, Education, 
Homelessness 
Utilisation health care, 
Employment,  Violence/Death, Education, 
Homelessness - non-adherence, partial 
adherence and non-compliance can arise a 
downward spiral of events leading to 
inconsistent symptom control, relapse and 
rehospitalisation, which in turn can lead to 
long-term functional disabilities, long-term 
negative outcomes (loss of autonomy, 
education or employment possibilities, 
homelessness, a likelihood of dropping out of 
care completely) and even suicide. 
(Marcus & 
Olfson, 2008b) 
 
USA 2008 Patients with 
schizophrenia 
Prospective, 
observa-
tional 
Non- 
adherence 
Utilization 
Health Care 
Utilization health care - antipsychotic non- 
adherence was related to an increase in 
hospitalisation rate, hospital days or hospital 
costs. 
(Mork et al., 
2013) 
Norway 2013 Patients with 
schizophrenia   
Cross-
sectional  
Untreated 
psychosis 
 Violence Violence - When compared with non-suicide 
attempters and those with suicide attempts 
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 without non-suicidal self-harm, patients with 
both suicide attempts and non-suicidal self-
harm were more frequently women, younger 
at the onset of psychotic symptoms, had longer 
duration of untreated psychosis, and had 
higher levels of current impulsivity/aggression 
and depression 
(Nielssen & 
Large, 2009) 
Australia 2009 Patients with 
psychosis  
Cross-
sectional 
Untreated 
psychosis 
Death Death- When looking at untreated psychotic 
illness in the survivors of violent suicide 
attempts, there appears to be a higher risk of 
violent suicide attempts during the first 
episode of psychosis than later in the illness. 
 
(Nielssen & 
Large, 2011) 
 
 
Australia 2011 Patients with 
schizophrenia 
and other 
psychoses 
Cross-
sectional  
Untreated 
psychosis 
Death Death- Psychosis is strongly associated with 
potentially lethal suicide attempts using sharp 
objects and patients who have never received 
treatment for psychosis appear to be at 
particular risk 
(Nielssen et 
al., 2012) 
 
 
International 
literature, 
unspecified 
2012 Patients with 
schizophrenia 
and other 
psychoses 
Literature 
review 
Untreated 
psychosis 
 Death Death- This overview of violence to self and 
others during the first episode of psychosis 
showed that a substantial proportion of first-
episode patients commit an act of less serious 
violence or attempt suicide prior to initial 
treatment. 
(Norman et 
al., 2012) 
 
 
Canada 2012   Prospective, 
observational 
Duration 
untreated 
psychosis, 
duration 
untreated 
illness (DUI) 
 Employment  Employment - Delay between onset of non-
specific symptoms and treatment (duration of 
untreated illness, DUI) was a more robust 
predictor of occupational functioning and use 
of a disability pension compared with DUP. 
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(Novick et al., 
2010) 
 
 
Denmark, 
Italy, 
Portugal, 
Spain, Ireland 
and the UK 
2010 Patients with 
psychosis  
Prospective, 
observational 
Non 
adherence 
Health Care 
Utilisation, Dea
th 
Utilization health care and death - Non-
adherence was significantly associated with an 
increased risk of relapse, hospitalisation and 
suicide attempts. 
OECD (2014) International 
literature, 
unspecified 
2014 Patients with 
schizophrenia 
and other 
psychoses 
Report Untreated  Employment,  
Death 
Employment - Mental illnesses have a huge 
labour market cost: OECD data suggests that 
one in five working age people have had a 
mental problem at some point in time, 
reducing their employment prospects, 
productivity and wages. The high costs of 
mental ill-health for society suggest a strong 
need for better services. Untreated mental 
illnesses can have a detrimental impact on 
wider society. Mild-to-moderate mental illness 
has been shown to have a strong relationship 
with higher unemployment, higher 
absenteeism, lower productivity in the 
workplace, and a rising burden of disability 
benefits claims across countries. Death- 
psychiatric illness is a major risk factor for 
suicide and it has been estimated that 90% of 
suicide attempters and completers suffer from 
at least one, mostly unrecognised, untreated, 
or inadequately treated mental illness. 
(Offord et al., 
2013) 
 
USA 2013 Patients with 
schizophrenia 
Prospective, 
observa-
tional 
Non- 
adherence 
Utilisation 
Healthcare 
Utilization health care - Early non- adherence 
is related to more hospitalizations (0.57 vs. 
0.38; P < 0.01) with longer length of stay (5.0 
vs. 3.0 days; P < 0.01) and higher costs ($5,850 
vs. $4,211; P = 0.02) compared with adherent 
patients. 
(Reininghaus UK 2008 Patients with Prospective, 
observa-
Duration 
untreated 
 Employment Employment - The authors confirmed 
association between untreated psychosis and 
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et al., 2008) 
 
 
psychosis  tional psychosis  unemployment; unemployed subjects were 
more likely to experience longer periods of 
untreated psychosis when reporting low (P < 
0.01) or medium (P <0.01) number of social 
contacts. No such difference could be observed 
for those with high social contacts (P = 0.60). 
(Šarotar et al., 
2008) 
 
 
Slovenia 2008 Patients with 
schizophrenia 
Retro-
spective, 
observ-
ational 
Duration 
untreated 
psychosis  
Employment, 
Education 
Employment - half of the patients with DUP 
longer than 1 year were on disability benefit as 
compared to 19% of patients who had received 
treatment with antipsychotic medication in the 
prodromal phase of the disease. Education - 
DUP longer than 1 year had a negative impact 
on the educational level achieved. 
(Schnapp WB, 
Burruss JW, 
Hickey S, 
Mortesen K, 
2009) 
 
USA 2009 Patients with 
schizophrenia 
and other 
psychoses 
Narrative 
review 
Untreated 
psychosis 
Use Of Criminal 
Justice 
Resources, 
Employment, 
Education, 
Death, 
Homelessness 
Use of criminal justice resources - For the 
Harris County, Texas, the 2008 costs of caring 
for the County’s incarcerated people with 
mental illness exceeded $48 million. 
Employment, Education/schooling, 
violence/death, Homelessness 
An insufficiently funded mental health service 
is reported to lead to societal productivity loss, 
homelessness, increased juvenile and adult 
criminal justice system involvement and 
decrease in life expectancy. More than 5.6 
billion dollars are lost every year in productivity 
and annual earnings as a result of severe 
mental illness. Education - untreated subjects 
often have difficulty in school and have an 
increased likelihood of becoming involved with 
the juvenile justice system. Death- In the USA 
over 15 percent of indirect costs of severe 
mental illness (treated and untreated cases) 
are related to mortality costs, or loss of 
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productivity due to premature death 
(Schimmelma
nn et al., 
2008) 
Australia 2008 Patients with 
first-episode 
psychosis 
Prospective, 
observational 
untreated 
psychosis 
Employment Employment - longitudinal study involving 786 
patients with first-episode psychosis (FEP). This 
study showed that duration of untreated 
psychosis is associated with a lower rate of 
employment/occupation (p<0.01). 
(Sun et al., 
2007) 
 
USA 2007 Patients with 
schizophrenia 
Modelling Non-
adherence 
Utilisation 
Healthcare 
Utilization health care - When modelling 
hospitalization costs associated with 
antipsychotic non adherence in the treatment 
of schizophrenia in the United States (Sun et 
al., 2007) estimated that the national re-
hospitalization costs related to antipsychotic 
non adherence was $1479 million, ranging 
from $1392 million to $1826 million in 2005. 
(Treur et al., 
2009) 
 
Germany 2009 Patients with 
schizophrenia 
Discrete 
event 
simulation 
model 
Non-
compliance 
Utilisation 
Healthcare 
Utilization health care - The authors 
considered two identical treatment arms 
except for percentage of compliant patients. 
The difference in compliance rates was varied 
from 0% to 15%, and incremental costs and 
effects were recorded and analysed.  With a 
5%, 10% and 15% difference in compliance 
rate, incremental effects increased to 0.021, 
0.037 and 0.062, respectively, while generating 
cost savings of Swedish kronor (SEK)31 500, 
SEK62 000 and SEK104 500, respectively 
(SEK9.25 = 1, Euro year 2007 values). On 
average, the model predicted that, with a 15% 
increase in compliance, 0.5 relapses were 
prevented, the average Positive And Negative 
Syndrome Scale (PANSS) score decreased by 
3.3 points and patients spent 22 fewer days in 
hospital over 5 years. 
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(Yee et al., 
2011) 
 
Australia 2011 Patients with 
schizophrenia 
and other 
psychoses 
Cross-
sectional  
Non- 
adherence 
 Violence Violence - When looking at severe non-lethal 
violence during psychotic illness, individuals 
who committed a severe violent offence were 
typically non-adherent to treatment, had co-
morbid substance use and prior criminal 
convictions. 
(Torres-
González et 
al., 2014) 
International 
literature, 
unspecified 
2014 Details are 
missing 
Narrative 
review 
Missed 
treatment 
Comorbidities Comorbidities - In schizophrenia, an increased 
likelihood risk for overweight, obesity, and 
abdominal obesity is present even in recently 
diagnosed and non-treated patients; however 
no economic estimates were available related 
to the impact of non-treating schizophrenia on 
its comorbidities. 
(Hong et al., 
2009) 
Germany, 
Italy, Spain, 
France, 
Denmark 
Greece 
Ireland/the 
UK the 
Netherlands 
and Portugal  
2009 Patients with 
schizophrenia 
Prospective, 
observational 
Non- 
adherence  
Utilisation 
Healthcare, 
Employment, 
violence 
suicide 
Use of health and social care resources - Our 
findings confirm the significant economic 
burden of relapse, and show such costs were 
mainly due to hospital stay. Costs incurred by 
patients who ever relapsed (£14,055) during 
three years were almost double to those 
incurred by patients who never relapsed 
(£7417). 61% of the cost difference was 
accounted for by hospital stay. The impact of 
relapse was even greater in the 1-year cost 
comparison.  
Employment - relapsers had an earlier onset of 
schizophrenia and had a poorer level of social 
functioning at baseline (i.e. a lower frequency 
of paid employment and social contacts in 
previous 4 weeks). 
Violence suicide - more relapsers (5.8%) had 
suicide attempts in the six months before 
baseline, compared to non- relapsers (3.3%). 
Cost and impact of non-treating severe mental illnesses (SMIs):  
The case study of schizophrenia                                                                      
 
 
111 
 
(Karve et al., 
2012) 
USA 2012 Patients with 
schizophrenia 
and other 
psychosis 
Prospective, 
observational 
Non- 
adherence 
Utilisation 
Healthcare 
Use of health and social care resources- 
Patients with psychiatric-related relapse events 
had all-cause and schizophrenia-related total 
medical costs approximately 2 times higher. 
Costs associated with schizophrenia-related 
inpatient service utilisation accounted for over 
69% of total schizophrenia-related total 
medical costs among patients with psychiatric-
related relapse events. Overall, these cost 
estimates are important in determining the 
additional direct economic burden exerted on 
the Medicaid system by such patients 
(Fazel et al., 
2014) 
Sweden 2014 Patients with 
schizophrenia 
and other 
psychosis 
Observational
, Longitudinal 
Non- 
adherence 
Violence Violence - Compared with periods when 
participants were not on medication, violent 
crime fell by 45% in patients receiving 
antipsychotics (hazard ratio [HR] 0·55, 95% CI 
0·47–0·64) and by 24% in patients prescribed 
mood stabilisers (0·76, 0·62–0·93) 
(Kudumija 
Slijepcevic et 
al., 2014) 
Croatia 2014 male in-patients 
with paranoid 
schizophrenia 
Cross-
sectional 
study 
Untreated 
psychosis 
Violence Violence - DUP before first contact with 
psychiatric services was a Predictor of violent 
offending together with older age, and alcohol 
abuse. 
(Látalová, 
2014) 
International  2014 Patients with 
psychosis 
Systematic 
literature 
review 
Untreated 
psychosis 
Violence and 
risk of 
homicide 
Violence - Available evidence suggests that the 
prevalence of violent behaviour in the first 
episode of psychosis, particularly 
schizophrenia, is greater than during the later 
stages of the illness. First-episode psychosis is 
associated with an increased risk of homicide. 
There is some limited support for an effect of 
DUP length on serious violence or aggression. 
Violent behaviour frequently develops before 
the onset of a first episode. 
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(Mojtabai et 
al., 2009) 
USA 2009 Patients with 
schizophrenia 
Narrative 
literature 
review and 
observational 
study 
Untreated 
psychosis, 
non-
adherence 
Utilisation 
Healthcare, co-
morbidities 
and 
homelessness 
Utilisation Healthcare – In epidemiological 
surveys, approximately 40% of the respondents 
with schizophrenia report that they have not 
received any mental health treatments in the 
preceding 6-12 months. Clinical 
epidemiological studies also find that many 
patients virtually drop out of treatment after 
their index contact with services and receive 
little mental health care in subsequent years. 
Clinical studies of patients in routine treatment 
settings indicate that the treatment patterns of 
these patients often fall short of the 
benchmarks set by evidence-based practice 
guidelines, while at least half of these patients 
continue to experience significant symptoms. 
The divergence from the guidelines is more 
pronounced with regard to psychosocial than 
medication treatments and in outpatient than 
in inpatient settings. The expansion of 
managed care has led to further reduction in 
the use of psychosocial treatments and, in 
some settings, continuity of care. In conclusion, 
we found a substantial level of unmet need for 
care among individuals with schizophrenia both 
at community level and in treatment settings. 
Comorbidities - The high prevalence of medical 
problems in patients with schizophrenia also 
calls for integration or better coordination of 
mental health and general medical services. 
There has been a renewed interest in the 
medical care of these patients, including 
receipt of the needed preventive and 
treatment services for chronic medical 
conditions and dental care. 
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Homelessness - Many patients with 
schizophrenia are at increased risk of 
homelessness and associated adverse social 
and health outcomes, such as victimisation and 
sexually transmitted diseases. 
(Haddad et al., 
2014) 
International 
including UK 
and USA 
2014 Patients with 
schizophrenia 
Narrative 
review 
Non- 
adherence 
Healthcare 
resources, 
criminal justice 
resources, 
violence 
Healthcare resources, criminal justice - In their 
literature review (Haddad et al., 2014) reported 
on the association between antipsychotic non-
adherence and outcome. Non-adherence was 
associated with a significantly higher rate of 
psychiatric hospitalisation, use of emergency 
psychiatric services, arrest, violence, 
victimization, and substance use plus poorer 
mental functioning, poorer life satisfaction, and 
more alcohol-related problems. 
(Fleischhacker 
et al., 2014) 
International 2014 Patients with 
schizophrenia 
Narrative 
review 
Non- 
adherence 
Healthcare 
resources, co-
morbidities, 
criminal justice 
resources, 
violence 
Healthcare resources – Long-term 
(maintenance) antipsychotic medication 
significantly reduces the number of relapses (at 
7–12 months) and the number of 
hospitalisations in patients with schizophrenia, 
compared with placebo (data from a combined 
analysis of 65 clinical trials) 
Comorbidities – Under-diagnosis and under-
treatment contribute to this high death rate. It 
should be a priority to develop and implement 
an evidence-based, integrated care package 
that addresses patients’ mental and physical 
health needs. 
Violence - good adherence to treatment 
appears to be associated with lower levels of 
aggression and people with schizophrenia who 
adhere to their treatment and are clinically 
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stable appear to be no more violent than the 
general population. Non-adherent individuals 
are more likely to have poor long-term 
function, to be violent and be arrested. 
(Sajatovic et 
al., 2009) 
International  2009 Patients with 
schizophrenia 
Narrative 
review 
Non- 
adherence 
Healthcare 
resources  
Healthcare resources - Based on data from 
patients with schizophrenia in the Medicaid 
program, there is evidence that the national re-
hospitalisation cost related to antipsychotic 
non-adherence was $1479 million in the United 
States in 2005 (Sun et al). Based on data from a 
large sample of patients treated for 
schizophrenia in the United States between 
1997 and 2003, Ascher-Svanum et al. reported 
that adherence to antipsychotics was 
associated with lower utilisation of acute care 
services and greater engagement in outpatient 
mental health treatment. 
(Barnes, 2011) International  2011 Patients with 
schizophrenia 
Narrative 
review 
Non- 
adherence 
Healthcare 
resources, 
criminal justice 
resources, 
violence 
Healthcare resources - Hospitalisation rates, 
which are a proxy marker for more severe 
relapse, are increased in non-adherent 
patients, with rates quoted of 150% (Knapp et 
al., 2004) 200% (Ascher-Svanum et al., 2006; 
Ward et al., 2006) and 400% (Morken et al., 
2008) over those found in adherent patients.  
Criminal justice resources, violence - Non-
adherent patients are more likely to use 
substances, be violent, be arrested (Ascher-
Svanum et al., 2006), attempt suicide (Leucht 
et al., 2006; Tiihonen et al. 2006; Ward et al., 
2006), and have poorer long-term functioning 
(Ascher-Svanum et al., 2006). 
(Morken et Norway 2008 Patients with Observational Non- Healthcare Healthcare resources - Odds Ratio of being 
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al., 2008) schizophrenia study adherence resources admitted to hospital was 4.00 among non-
adherent patients compared to adherent 
group. 
(Weiden et al., 
2004) 
USA 2004 Patients with 
schizophrenia 
Observational 
study 
Non-
compliance/a
dherence 
Healthcare 
resources 
Healthcare resources - Risk of hospitalisation 
was significantly correlated with compliance. 
Lower compliance was associated with a 
greater risk of hospitalisation over and above 
any other risk factors for hospitalisation. For 
example, the presence of any gap in 
medication coverage was associated with 
increased risk of hospitalisation, including gaps 
as small as one to ten days (odds ratio 
[OR]=1.98). A gap of 11 to 30 days was 
associated with an OR of 2.81, and a gap of 
more than 30 days was associated with an OR 
of 3.96. 
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